Рекомендации Международной группы по работе с миеломой по диагностике и лечению изолированных плазмоклеточных опухолей.

INTRODUCTION

Plasmacytomas are localized tumors of clonal plasma cells. Solitary plasmacytomas (SPs) are defined as biopsy-proven, single-site clonal plasma cell tumors, 1 - 3 as opposed to the systemic nature and the more diffuse infiltration of the bone marrow (BM) in multiple myeloma (MM). 2 This definition requires proven plasma cell clonality and a single tumor site (solitary), without evidence of significant BM infiltration (ie, should be <10% clonal plasma cells) or systemic disease. Most plasmacytomas occur within a bone, typically but not exclusively as a single lytic lesion, and are referred as solitary bone plasmacytoma (SBP). Less common are solitary extramedullary plasmacytomas (SEMP) in which the plasma cell tumors are found in a single nonbony (extraosseous/extramedullary) site. 4 - 10 Direct invasion or expansion from a bone to an adjacent nonbony (soft tissue) site does not constitute a SEMP; such tumors are called paraskeletal and managed like SBP. About 50%-70% of patients with SBPs and approximately 30% of patients with SEMPs will progress to MM within 5 years after treatment with local radiotherapy. 4 , 5 , 11 - 19

Since the International Myeloma Working Group (IMWG) diagnostic criteria 2 for MM publication, the widespread use of sensitive imaging modalities for detection and follow-up of solitary lesions and methods for clonality detection have refined diagnostic definitions, treatment, and follow-up of SPs and continue to evolve.

INCIDENCE

SPs are rare, comprising approximately 3%-6% of plasma cell disorders. 20 - 24 In a SEER analysis (2003-2016) overall age-adjusted incidence rates per 100,000 adults were 0.45 for SBP, 0.12 for SEMP, and 8.47 for MM. 22 In a US study (2000-2019), the age-standardized incidence (per 100,000 men and women, respectively) for SBPs were 0.38 and 0.20 and for SEMPs were 0.13 and 0.06. Age-standardized SEMPs incidence declined (especially among women) but not for SBPs during this period. 21 SP incidence is higher among men (twofold for both SBP and SEMP), 20 , 22 , 25 - 28 and in Black patients and the lowest in Asian/Pacific Islanders. The median age at SP diagnosis is 55-60 years, about a decade younger than in MM. 20 , 22 , 25 - 28

TOPOGRAPHY AND CLINICAL PRESENTATION

Patients with SBP usually present with localized bone pain and/or fracture at the lesion site, less often with neurologic symptoms from spinal cord compression in cases with vertebral involvement. The axial skeleton, particularly sites with active hematopoiesis, is more often involved (thoracic vertebrae more common, pelvis, ribs, upper extremities, skull, femur, sternum); distal appendicular SBPs are uncommon. 4 , 14 , 15 , 29 , 30 Patients with SBPs should not have systemic symptoms attributable to the plasma cell clone; if present, further evaluation is needed. Patients with SBP presenting with peripheral neuropathy should be evaluated for polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome or, rarely, light-chain amyloidosis 31 , 32 (Data Supplement, Table S1).

SEMPs typically arise at mucosal sites with high antigenic load, more common in the head and neck region (85%) 26 , 27 , 33 , 34 ; other sites include the GI tract, lung, thyroid, testis, parotid glands, lymph nodes, and CNS. 35 , 36 Symptoms should, by definition, only be related to local tumor expansion.

PATHOPHYSIOLOGY OF SPs

The clinical course of SPs is typically more indolent than MM although the biologic basis for these differences remains incompletely understood. The localized aggregation of the clonal cells ( v scatter in MM) suggests a critical role of interactions with their microenvironment. 37 The localization in bone, for SBPs, versus mucosal surfaces, for SEMPs, suggests differences in their antigen-driven development. Clonal PCs in SPs and MM have similar immunophenotypes, despite subtle differences (eg, lower frequency of CD56 expression in SEMPs) 4 and carry similar cytogenetic alterations. Interphase fluorescence in situ hybridization (FISH) commonly identifies del(13q; 33%-40%), immunoglobulin heavy chain (IgH) rearrangements (37%-53%), and hyperdiploidy (45%-54%). 38 - 40 The presence of IgH translocations point to a common origin of SPs and MM. 39 In a Mayo Clinic series of 55 patients, high-risk cytogenetic abnormalities [del(17p), t(14; 16), t(4; 14), +1q21(gain or amplification)] were seen in 40% (22/55), with del17p found in 20%(11/55); their presence was associated with short progression time to MM (approximately 8 months). 40 In an Intergroupe Francophone du Myélome cohort, targeted next generation sequencing (NGS) performed on 47 patients with SBPs identified hyperdiploidy in 64% while 59% harbored MAPK pathway mutations ( KRAS , NRAS , and BRAF ) and 19% had a TP53 alteration (del17p and/or TP53 mutation). KRAS mutation or TP53 abnormality was associated with inferior progression-free survival. High Ki-67 expression (>20%) also correlated with adverse risk, suggesting that molecular lesions already shape disease evolution at this early stage. 41 Some reports indicate that SEMPs tend to have fewer cytogenetic abnormalities when compared with MM; in a series of 38 patients with SEMPs, there were no patients with t(11; 14), but six (16%) had t(4; 14). 38

Patients with SBPs more often have minimal BM involvement and/or detectable monoclonal proteins compared with SEMPs 4 , 8 , 42 and exhibit a higher rate of progression to overt MM, which could partly be explained by the above differences.

DIAGNOSTIC CRITERIA

Current Definitions

The diagnosis of SP requires (a) histologic and immunohistochemical confirmation of a monoclonal plasma cell tumor; (b) the absence of additional lesions in the skeleton or outside the skeleton, assessed by advanced functional imaging; (c) the absence of significant (ie, ≥10% clonal plasma cells by immunohistochemistry [IHC]) BM involvement; and (d) the absence of myeloma defining events. 2

The term solitary plasmacytoma with minimal marrow involvement encompasses patients in whom clonal plasma cells are present in the BM, but the clonal plasma infiltration by IHC is <10%. The two different conditions (without and with minimal marrow involvement) carry different risks of progression to MM and should be reported separately (Fig 1 ).

Histologic Diagnosis

Both SBPs and SEMPs are characterized by the presence of mature plasma cells, expressing CD138 and/or CD38, with light chain restriction. Clonality is usually assessed with IHC or PCR-based methods. 43 , 44

The histologic diagnosis of SEMPs may be challenging, 45 requiring an experienced hematopathologist. Malignant plasma cells in SEMP may exhibit a plasmablastic morphology, but compared with the extramedullary MM involvement, CD56 expression is less frequent, and proliferation rate is lower. A histologic three-grade classification developed for SEMP is not widely used. 46 A SEMP variant, with predominantly IgA expression, manifests in head and neck lymph nodes, in younger patients with immune dysregulation. 47

In some SEMP cases, an accompanying neoplastic B-cell population raises the possibility of an extranodal marginal zone or lymphoplasmacytic lymphoma (Table 1 ). Plasma cells immunophenotype can help because B-cell lymphomas with plasmacytic differentiation contain clonal plasma cells more like their normal counterparts. Localized amyloid deposits are common and do not necessarily indicate systemic AL amyloidosis but warrant further evaluation to exclude systemic involvement. 48 - 56 Notably, the clonal cells may be missed within the amorphous material, and careful evaluation is needed to confirm clonality.

Plasmablastic lymphoma, commonly involves the oral cavity or mucosal surfaces, exhibits plasmablastic morphology, typically in immunocompromised individuals, and is frequently associated with Epstein-Barr virus (EBV). Morphologic and immunohistochemical studies cannot always differentiate between plasmablastic lymphoma and SEMP; markedly increased proliferation rate, necrosis, and association with EBV infection, as well as aggressive clinical presentation, suggest plasmablastic lymphoma rather than SEMP; a rare EBV-positive SP has also been described. 57

Differential diagnosis of SPs includes both nonmalignant and malignant tumors such as fibrous dysplasia, enchondromas, 58 - 60 POEMS and adenopathy and extensive skin patch overlying a plasmacytoma (AESOP) 32 , 61 - 64 syndromes, Castleman disease, and metastatic solid malignancies. The differential diagnosis also includes nonmalignant conditions (reactive plasmacytosis, plasma cell granuloma, 65 and IgG4 disease, 66 Table 2 ). Careful evaluation is needed in patients with a monoclonal gammopathy, when histology reveals the possibility of a metastatic tumor. In most cases, the diagnosis is straightforward; however, if the material is limited and polyclonal plasma cells are present, additional confirmatory studies are needed.

IMAGING

Advanced whole-body (WB) functional imaging is critical to exclude the presence of additional lesions and for follow-up after treatment (Table 3 ; Fig 2 ).

Radiographs and Computed Tomography (CT) Scan

Plain x-rays lack sensitivity within the axial skeleton and is not a valid option. 67 - 71 Low-dose WB CT scan (ldWBCT) can detect even small (<5 mm) lytic bone lesions but has not been studied in SPs. ldWBCT is preferred over plain x-rays, 72 , 73 but lacks sensitivity for early or nonosteolytic marrow disease, cannot distinguish active from inactive lesions, being unsuitable for response assessment, offers limited soft-tissue contrast, and cannot evaluate SEMPs. ldWBCT can be considered only if WB functional imaging is unavailable, ideally in combination with axial magnetic resonance imaging (MRI).

MRI

MRI detects plasma cell BM or soft tissue infiltration, identifying focal lesions (FLs) or diffuse BM infiltration before osteolysis appearance, paraskeletal disease, spinal cord/nerve root impingement or compression, 74 and extramedullary lesions. It is the preferred technique for CNS lesions. MRI of the spine and pelvis detected focal or diffuse BM involvement in >25% of patients falsely diagnosed as SBPs based on conventional radiographs 74 , 75 and was associated with the persistence of monoclonal protein after radiotherapy and higher relapse rates. 70 , 74 - 76 Nonetheless, in the study by Paiva et al 44 , MRI was negative in 12/28 (43%) patients with clonal cells detected by next generation flow cytometry (NGF)/multiparametric flow cytometry (MFC).

Diffusion-weighted imaging (DWI-MRI) is sensitive for tumor detection in SMM and MM, but prospective data in SPs remain limited. WB-MRI (DWI) is used for disease staging and response evaluation according to myeloma response assessment and diagnosis system (My-RADS) criteria and included in the revised response criteria and guidelines, 77 is highly recommended over standard axial MRI, and is strongly considered as alternative to positron emission tomography (PET)/CT. 78 If WB-MRI (DWI) is not available or expertise in interpreting and reporting is lacking, a combination of axial MRI and PET/CT is alternatively recommended.

PET/CT

18 F-FDG-PET/CT combines valuable metabolic and anatomic assessment for SP evaluation. In small studies, FDG-PET/CT reveals additional lesions in 33%-55% of plain radiographs-presumed SBP cases. 79 Compared with axial-MRI, PET/CT has lower sensitivity to detect diffuse BM involvement and FLs but has wider coverage. 80 - 84 Baseline PET/CT provides additional prognostic information with higher avidity lesions associated with an increased risk of progression. 16 , 79 IMWG acknowledges the value of PET/CT in the management of SP and state that, in the context of limited WB MRI availability, PET/CT should be part of initial SP investigation to exclude additional occult disease. 69 , 79 In SEMPs, PET/CT is the preferred imaging modality to exclude additional lesions. 67 PET-CT can be used to evaluate response to therapy applying the standardized Italian Myeloma Criteria for PET Use (IMPeTUs) criteria. 85 Importantly, lesions may remain FDG-avid for months after radiotherapy, and this should not prompt immediate therapy escalation but close follow-up. Other PET metrics, including total lesion glycolysis, remain investigational.

All patients with SPs should have advanced functional imaging at diagnosis.

FDG-PET/CT and/or WB MRI (DWI) are preferred imaging modalities to exclude additional lesions and for accurate evaluation of treatment response.

The most sensitive available imaging modality should be used at baseline, and the same should be used to assess treatment response, according to standardized criteria

BM Assessment

BM should show no or minimal clonal infiltration (ie, <10% clonal PCs by IHC), reported as SP with minimal marrow involvement. 43 , 86 - 90 Sensitive techniques (MFC/NGF, NGS) detect even small clonal populations, 91 more often than IHC (in 21%-68% of patients with SBPs), but less (approximately 38%) in SEMPs. 40 , 43 , 44 , 92 In SBPs, clonal BM PCs detected by MFC/NGF were associated with a higher risk of progression to MM, 43 , 44 but this was not shown in SEMPs. 44 In a study of SBPs, the presence of minimal marrow involvement (by IHC or aspirate or by MFC/NGF) was associated with shorter time to MM in univariable (N = 115 patients, 28 v 53 months, P = .018), 40 but not in multivariable analysis. In a more recent report, from the same center, BM involvement (N=147, mostly patients with SBP) was strongly associated with shorter time to MM progression (15.7 v 79 months; P < .001). 19

High sensitivity of MFC/NGF (10 −5 -10 −6 ) increases detection of minimal marrow involvement. The extent of BM involvement by MFC/NGF may be clinically important but prognostic comparison of minimal marrow involvement by NGF versus IHC is lacking. IMWG strongly encourages BM evaluation with sensitive assays and reporting of the results because they provide prognostic information and may aid treatment evaluation in the context of future clinical, imaging, and biochemical findings. Circulating tumor (plasma) cells are detected in approximately 18% of SPs 93 ; however, their prognostic significance is unknown. NGS-based methods can detect minimal BM involvement using DNA sequencing of the original SP to identify the clone-specific immunoglobulin gene rearrangements in the BM or by high-throughput Ig repertoire sequencing on RNA. 91 However, the clinical implications of such sensitive approaches are unknown.

The most sensitive available method should be used to detect clonal BM disease. A BM aspirate without a trephine for IHC or sensitive flow cytometry is inadequate.

Evaluation with MFC/NGF (or NGS, if available) is recommended for all patients with SBP and SEMP.

BM or the SP assessment for the presence of cytogenic aberrations by FISH or NGS is strongly recommended.

The IMWG definition of SPs without and SPs with minimal marrow involvement remain and should be reported separately, along with the methods used to assess BM involvement.

Until more data are available, patients with SPs should have a similar treatment approach, irrespective of the presence of minimal marrow involvement.

ASSESSMENT OF MONOCLONAL PROTEINS

All patients with SPs must have complete assessment for the presence of monoclonal immunoglobulin(s) and free light chains in serum and urine before treatment initiation (Table 3 ; Fig 2 ). Serial assessments have prognostic value. 6 , 11 , 18 , 30 , 75 , 94 - 96 Approximately 50%-80% of patients with SBP have a small M-protein (median 0.5-0.9 g/dL) and 40%-60% have abnormal FLC ratio with negative urine and serum immunofixation. 4 , 18 , 19 , 97 In SEMPs, serum and urine immunofixation studies are abnormal in <25%-45% of patients. 18 , 26 , 76 Immunoparesis is rare; if present, more extensive disease should be suspected. 75 , 97 The role of mass spectrometry to detect low M-protein levels or post-therapy monitoring in SPs has not been evaluated. 98

Complete serum and urine tests to detect any monoclonal immunoglobulin is required in all patients before treatment initiation and at follow up post-therapy.

Mass spectrometry is not routinely recommended yet, but it is encouraged to be reported.

PROGNOSTIC FACTORS

The Data Supplement (Table S2) summarizes baseline tumor characteristics and treatment-related factors associated with prognosis of SPs. Some prognostic scores (Data Supplement, Table S3) which have been developed in relatively small series lack external validation. IMWG strongly encourages collaboration for identification of prognostic factors.

TREATMENT

Radiotherapy

Local radiotherapy with curative intent is the treatment of choice for SPs with 83%-96% of patients achieving response. 5 - 7 , 9 , 11 , 13 - 15 , 17 , 18 , 25 , 30 , 33 , 42 , 99 - 108 No prospective randomized studies define optimal radiation dose. Retrospective data suggest inferior outcomes with doses <40 Gy, 26 , 42 , 109 whereas doses >45 Gy do not significantly improve tumor control 5 - 7 , 9 , 11 , 14 , 15 , 17 , 30 , 33 , 42 , 99 - 102 except in few cases. 13 , 103 , 104 Few studies suggest a dose-response curve for larger SBPs. 104 Some centers follow a risk-adapted approach delivering 50 Gy over 25 fractions for SPs >5 cm and 40 Gy in 20 fractions for SPs <5 cm. 105 The National Comprehensive Cancer Network guidelines (V.4.2026) recommend 40-50 Gy dose in 1.8-2.0 Gy fractions (20–25 total fractions) to the involved site, with a 35-40 Gy dose acceptable for SPs <5 cm in size. The International Lymphoma Radiation Oncology Group (ILROG) recommends a total dose of 35-40 Gy for SBPs <5 cm (with 35 Gy acceptable for small SBPs) and 40-50 Gy for SBPs ≥5 cm; a 40-50 Gy total dose is recommended for SEMPs, with 40 Gy being acceptable for small, well-defined lesions or with postexcision positive margins. 110

Lower doses used for palliation in MM patients with plasmacytomas are insufficient for local control and are not recommended for SPs. 108 , 111 - 114

In rare cases with two disease sites and no evidence of systemic involvement, it is unclear whether management should follow MM principles (as in macrofocal MM 115 ) or local therapy only. In one study, survival did not differ between patients with a single or two lesions, 116 but patients with >2 lesions had inferior outcomes. For patients with two lesions, especially if located in the same area and without marrow involvement, local therapy for both lesions and close observation with advanced imaging is reasonable; however, this approach is not recommended if one or both are large (ie, >5 cm).

Modern radiotherapy techniques (ie, intensity-modulated radiotherapy [IMRT], volumetric-modulated arc therapy [VMAT], and protons) should be used over conventional radiotherapy to limit toxicity. 12 , 110 , 117 Involved-site radiotherapy (ISRT) should be used to avoid large radiation fields, 101 , 110 , 118 which should be defined with precision and not on gross anatomic landmarks. ILROG recommends to define a clinical target volume (CTV) that includes the gross tumor volume (GTV), on the basis of the primary imaging of untreated lesions, plus a margin of 0.5-3 cm expanded in all directions, respecting anatomic boundaries; an axial GTV to CTV expansion of 0.5-1 cm may be appropriate for potential microscopic extension in soft tissues. 110 Modern techniques allow for definitive radiotherapy in organs such as the aerodigestive tract, eye, etc. The benefit of extensive coverage or prophylactic nodal radiotherapy is controversial, 9 , 34 , 76 , 101 , 117 , 119 - 123 particularly for SEMPs involving the Waldeyer ring.

If the radiation field is particularly large or includes a tissue/organ at a high risk of subsequent side effects, systemic therapy may be considered instead of RT; however, no prospective comparative data are available. Steroids should be used with caution (ie, for nerve root or spinal cord compression or to prevent pain flare) because they may affect the detection of M-protein after radiotherapy.

Radiotherapy remains the recommended treatment for all patients with SPs, irrespective of minimal marrow involvement.

Doses of radiotherapy of 40 to 50 Gy in 20-25 fractions are recommended for all SPs

Modern radiotherapy techniques (IMRT, VMAT) should be used.

Radiation fields should be defined precisely and not by gross anatomic boundaries.

Regional lymph nodes irradiation is not required for SEMPs

Surgery

Partial or complete surgical excision may be performed during the diagnostic workup, particularly for SEMPs. For SBPs, surgery may be indicated or considered for vertebral instability, spinal cord compression (laminectomy, vertebroplasty, and kyphoplasty 124 - 127 ), or pathologic or imminent fracture risk. 128 Surgery does not replace radiotherapy either for SBPs nor for SEMPs: Local recurrence rates with tumor excision only are high, 14 and tumor bed radiotherapy should be strongly considered postresection.

For SEMPs, local control improves when surgery is followed by radiotherapy. 10 An older literature review reported similar outcomes for surgery with clear margins, radiation, or a combined modality approach 129 ; however, given the radiosensitivity of SEMPs, radiation therapy remains the preferred approach. 110 , 120 , 130 Radiotherapy is strongly recommended following a surgery without clear margins or when complete excision is associated with functional impairment or has significant risks. 7 , 101 , 120 , 121 In selected cases, surgery may be considered for special sites or for the management of specific complications. 35 , 131 - 133

Surgery does not replace radiotherapy but may be done if clinically necessary, followed by radiotherapy

Tumor excision alone is an inadequate treatment but may be considered in exceptional cases (small SEMPs excised with adequate margins).

Systemic Therapy

Prospective data on the role of adjuvant or concurrent systemic therapy in SPs are limited. A small, randomized study conducted between 1982 and 1989 favored combined therapy 134 but lacked modern imaging and used outdated systemic therapy. A US Alliance Cooperative Group study investigated zoledronate with or without ixazomib-(I), lenalidomide-(R), and dexamethasone-(d) for six 28-day cycles following definitive radiation but closed prematurely because of poor accrual; six IRd-treated patients had a 33% (95% CI, 0 to 70) 4-year progression rate to myeloma while five nontreated patients had a 58.3% (95% CI, 0 to 85.3) 2-year progression rate. In a nonrandomized study, 46 patients with SP treated between 2007 and 2018 received IMRT (median total dose of 40 Gy) while concurrent lenalidomide-dexamethasone (starting with radiation therapy, for four cycles, in n = 19) was given per physician's discretion. The 5-year myeloma-free survival was 100% with the combination versus 77.1%, P = .02 and progression-free survival was 81.7% versus 48.4%, P = .047, respectively. 12 A retrospective SBP series (N= 77) treated with radiation with or without systemic therapy showed marginal benefit, 96 but patients who received adjuvant therapy had more frequently minimal marrow involvement and almost all persistent M-protein after radiotherapy. 96 Other case series provide conflicting results with few indicating some 7 , 13 , 42 , 135 - 137 and most no benefit 4 - 6 , 8 , 9 , 18 , 95 , 100 , 117 , 138 - 140 of systemic therapy. Retrospective studies lack information on imaging, BM assessment, and occult systemic disease and use systemic therapy more frequent in patients with larger plasmacytomas or with nonoptimal imaging response after radiotherapy, and most have not used novel agents. Most regimens are of fixed duration. Systemic use of bisphosphonates has not been studied in SPs. The optimal regimen with respect to adjuvant therapy is unknown, given the available options. There are anecdotal reports of anti-CD38 monoclonal antibodies use or their combinations, but lacking prospective data. Ongoing trials evaluate combined approaches (ClinicalTrials.gov identifiers: NCT06863584 , NCT05248633 , NCT02544308 ).

Given the availability of advanced imaging to assess response and detect progression early, the effective salvage options, and limited data, we do not recommend systemic adjuvant therapy outside clinical trials. IMWG acknowledges that there may be situations where clinical judgment favors systemic treatment for individual cases, for example in patients in which radiation therapy may not be feasible or deemed too toxic. Further studies are needed to bring clarity on this topic.

Adjuvant or concurrent systemic therapy is not recommended when adequate radiotherapy is delivered, irrespective of SP size or minimal marrow involvement.

Decisions on systemic therapy should be based on postradiotherapy response evaluation. This approach may change as data on novel combinations, especially in patients with minimal marrow involvement, emerge.

RESPONSE ASSESSMENT AND FOLLOW-UP

The goal of therapy is complete tumor disappearance and laboratory normalization. Functional/advanced WB imaging combined with biochemical evaluation is recommended after therapy (Fig 2 ).

Response assessment requires functional imaging , performed 6-9 months after radiotherapy, with the same imaging modality as baseline, following local availability and interpretative expertise, and guided by clinical circumstances. Physicians should be aware that early assessment (ie, at 3 months), sometimes considered for specific clinical reasons or in case of suspected progression, can result in false-positive scans because of radiotherapy-induced changes or BM regeneration. Both bone destruction/regeneration in SBPs and fibrotic tissue in SEMPs vary among patients, and visible alterations may persist for years. Standard MRI may give false-positive results for months following radiotherapy and should be interpreted cautiously. Functional imaging using WB-MRI (DWI) or FDG-PET/CT are the recommended imaging modalities according to the standardized interpretative criteria (MY-RADS and IMPETUS) . 78 , 141 Each evaluation should be compared with the pretreatment imaging results.

In case of imaging complete remission (per the above criteria), repeat functional imaging, ideally using the same method/machine as baseline, is suggested annually for the first 5 years, or sooner if signs of progression emerge.

For those with residual or doubtful tumor mass at the 6-9 months evaluation (ie, partial response/stable disease by PET or RAC-2 and 3 by MRI, per standardized criteria), reimaging every 6 months can be considered, until complete response or any residual abnormality remains stable on consecutive scans (meaning false-positive imaging results, mostly because of tissue remodeling). It is generally not beneficial to continue to reimage stable minor residual abnormalities frequently, unless there are clinical indications; switching imaging method can be considered as cross-check. Only PET-defined progression or RAC 4-5 by MRI should be considered as progressive disease (Fig 2 ).

M-protein should disappear with successful treatment, but can be slow (median 3-6 months, or longer 6 ), requiring serial measurements. Persisting M-protein is more frequent among patients with minimal marrow involvement and predicts a higher progression risk. 6 , 11 , 30 , 75 , 94 - 96 Isolated presence of M-protein should not trigger immediate start of systemic therapy , and careful follow-up is recommended.

The follow-up should include regular clinical assessment with serum and urine testing for persistent M-protein (eg, at 3 months postradiotherapy and every 6 months thereafter). There are no data to support frequent BM reassessment after radiotherapy, especially in patients with negative baseline tests.

Response assessment requires advanced functional imaging (PET/CT or WB-MRI-(DWI)) performed 6-9 months after radiotherapy, interpreted according to MY-RADS and IMPETUS criteria, respectively.

In patients with imaging complete remission, annual functional reimaging is suggested for the first 5 years, or earlier if clinically indicated.

For residual tumor masses with partial response, re-evaluation every 6 months can be considered, until complete response or stable residual disease; switching imaging modality can be considered as cross-check.

M-protein should be followed every 3-6 months; delayed disappearance is common, and its persistence is associated with a higher risk of progression to MM but should not trigger immediate start of systemic therapy.

BM re-evaluation is not recommended routinely, unless clinically indicated.

OUTCOMES AND PROGRESSIVE DISEASE

Patients with SPs generally have favorable overall survival (OS), although outcomes vary by subtype, lesion location, and individual prognostic factors. Population-based data from the United States, 10 , 142 Germany, 142 Sweden, 24 Mayo Clinic, 19 , 89 and Greece 4 , 18 consistently demonstrate better 10-year survival than patients with MM treated in the same era. These findings suggest that SPs carry a more favorable prognosis compared with MM, underscoring the importance of avoiding unnecessary systemic therapy to preserve quality of life and limit late complications.

Approximately 50% of patients with SBP progress to MM within 3-5 years after local radiotherapy, with 10-year progression rate reaching 65%-84%. 4 , 5 , 11 - 18 Despite their accuracy, even patients with negative WB-MRI or PET/CT may eventually develop MM. Patients with SBPs can develop new lesions without evidence of diffuse marrow involvement, either solitary or multiple (as in macrofocal MM), 7 , 25 , 88 , 89 , 95 , 103 , 115 , 140 or progress to typical MM with marrow involvement 42 , 136 ; even localized recurrences can occur within or near the radiation field 7 , 9 , 30 (Fig 3 ). The majority, however, will present with new focal/lytic lesion(s) and low tumor burden disease.

Local recurrence rates for SEMPs are around 10%, 15 , 27 , 76 , 94 , 99 , 143 and progression to MM ranges from 11% to 36% (significantly lower than with SBPs). 15 , 26 , 94 Relapse may manifest with lymph node infiltration, skin and subcutaneous tissues involvement, or development of lytic bone lesions. Patients progressing to MM usually have relatively indolent disease with features of low tumor burden. 94 , 115 , 144

Isolated localized relapses should be carefully re-evaluated with advanced imaging. Radiotherapy can still be used for a solitary lesion outside the radiation field. For recurrences near or within the radiation field, previous radiotherapy dose and fields must be reviewed to evaluate the possibility of additional doses at the same location. Primary resistance to radiotherapy is exceptionally rare; such cases should be reviewed carefully (including revisiting the diagnosis and imaging), especially if the evaluation included only one imaging modality that was repeated early after radiation. 16 , 69 , 79 , 80 , 85 , 145 - 149 Localized amyloid deposits within the plasmacytoma may limit a response in size after radiotherapy. Close observation with repeated imaging is advisable before characterizing the disease as radiotherapy resistant. In cases of true resistant disease or if an effective radiation dose cannot be delivered, systemic therapy should be considered after restaging for MM and ruling out other diagnoses. Some data suggest a role of percutaneous cryoablation in selected patients with recurrent plasmacytomas after radiotherapy. 150

If progression to overt MM occurs, standard MM systemic treatment principles apply. The prognostic impact of prior SBP or SEMP to the outcome of MM therapy (compared with patients with MM without a history of SP) is unknown, but many patients who progress after SPs tend to have relatively low-stage disease; close monitoring and early identification of the disease may also contribute to better prognosis. Patients progressing to overt myeloma should not be excluded from MM frontline trials.

ACKNOWLEDGMENT

We thank all the IMWG members that provided constructive comments and suggestions for this paper (IMWG members are listed in the Appendix , online only).

APPENDIX: List of International Myeloma Working Group Members

1. Hikmat Abdel-Razeq, King Hussein Cancer Center, Amman, Jordan

2. Nadine Abdullah, Mayo Clinic, Rochester, MN

3. Masahiro Abe, Tokushima University, Tokushima, Japan

4. Niels Abildgaard, Odense University Hospital, Odense C, Denmark

5. Rafat Abonour, University of Miami, Miami, FL

6. Ingerid Abrahamsen, Oslo University Hospital, Oslo, Norway

7. Aimaz Afrough, University of Texas Southwestern Medical Center, Dallas, TX

8. Sikander Ailawadhi, Mayo Clinic, Jacksonville, FL

9. Samer Al Hadidi, University of Arkansas for Medical Sciences, Little Rock, AR

10. Adrian Alegre, Universitary Hospital La Princesa, Madrid, Spain

11. Melissa Alsina, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

12. Kenneth Anderson, Dana-Farber Cancer Institute, Boston, MA

13. Larry D. Anderson Jr., UT Southwestern Medical Center, Dallas, TX

14. Frida Askeland, Oslo University Hospital, Oslo, Norway

15. Shelbi Atrash, Levine Cancer Center, Charlotte, NC

16. Hervé Avet-Loiseau, Institut Universitaire du cancer de Toulouse Oncopole, Toulouse, France

17. David Avignon, Dana Farber Cancer Institute, Boston, MA

18. Ashraf Badros, University of Maryland, Baltimore, MD

19. Nizar Jacques Bahlis, University of Calgary—Arnie Charbonneau Cancer Institute, Calgary, Canada

20. Susan Bal, University of Alabama at Birmingham, Birmingham, AL

21. Muahamed Baljevic, Vanderbilt University Medical Center, Nashville, TN

22. Rahul Banerjee, Fred Hutchinson Cancer Center, Seattle, WA

23. Linda Baughn, Mayo Clinic, Rochester, MN

24. Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

25. Meral Beksaç, Ankara Liv Hospital, Istinye University, Ankara, Turkey

26. Dina Ben-Yehuda, Hadassah University Hospital, Jerusalem, Israel

27. William Bensinger, Swedish Cancer Institute, Seattle, WA

28. Jesús G. Berdeja, Sarah Cannon Research Institute, Nashville, TN

29. P. Leif Bergsagel, Mayo Clinic, Scottsdale, AZ

30. Manisha Bhutani, Atrium Health Levine Cancer Institute, Charlotte, NC

31. Giada Bianchi, Dana Farber Cancer Institute, Boston, MA

32. Noa Biran, Hackensack University Medical Center, Hackensack, NJ

33. Jenny Bird, University Hospitals Bristol and Weston NHS Trust, Bristol, United Kingdom

34. Joan Blade, Hospital Clínic Barcelona, Barcelona, Spain

35. Maria Jesus Blanchard, H.U Ramon y Cajal, Spain

36. Mario Boccadoro, Città della Salute e della Scienza di Torino and University of Turin, Turin, Italy

37. Thorstein Boxaspen, Oslo University Hospital, Oslo, Norway

38. Andrew Branagan, Massachusetts General Hospital, Boston, MA

39. Annamaria Brioli, Hannover Medical School, Greifswald, Germany

40. Annemiek Broyl, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

41. Christian Bryant, NSW Health Pathology, Australia

42. Francis Buadi, Mayo Clinic, Rochester, MN

43. Mark Bustoros, Weill Cornell Medicine, New York, NY

44. Jo Caers, Centre Hospitalier Universitaire de Liège, Liège, Belgium

45. Natalie Callander, University of Wisconsin Carbone Cancer Center, Madison, WI

46. Michele Cavo, Bologna University School of Medicine—S.Orsola Hospital, Bologna, Italy

47. Claudio Cerchione, Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”—IRST IRCCS, Italy

48. Rajshekhar Chakraborty, Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY

49. Asher Chanan-Khan, Mayo Clinic, Jacksonville, FL

50. Ajai Chari, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

51. Wen-Ming Chen, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China

52. Marta Chesi, Mayo Clinic, Scottsdale, AZ

53. J. Anthony Child, University of Leeds, Leeds, United Kingdom

54. Chor Sang (James) Chim, University of Hong Kong, Queen Mary Hospital, Hong Kong, China

55. Wee Joo Chng, National University Cancer Institute, Singapore

56. Diana Cirstea, Mass General Hospital, Boston, MA

57. Adam Cohen, University of Pennsylvania, Philadelphia, PA

58. Yael Cohen, Tel Aviv Sourasky Medical Center, Isreal

59. Craig Cole, Karmanos Cancer Institute, Detroit, MI

60. Raymond Comenzo, Tufts University School of Medicine, Boston, MA

61. Rebecca Connor, UpToDate, Waltham, MA

62. Gordon Cook, University of Leeds, England, United Kingdom

63. Joselle Cook, Mayo Clinic, Rochester, MN

64. Jill Corre, Centre Hospitalier Universitaire de Toulouse, Toulouse, France

65. Luciano Costa, University of Alabama at Birmingham, Birmingham, AL

66. Caitlin Costello, University of California San Diego Health, La Jolla, CA

67. Andrew Cowan, Fred Hutchinson Cancer Center, Seattle, WA

68. Peter Croucher, Garvan Institute of Medical Research, Australia

69. Edvan Crusoe, Federal University of Bahia University Hospital, Salvador, Brazil

70. Anita D'Souza, Medical College of Wisconsin, Wauwatosa, WI

71. Faith Davies, NYU Langone Health Perlmutter Cancer Center, New York, NY

72. Javier de la Rubia, Hospital Universitario La Fe, València, Spain

73. Carmino de Souza, Univeridade de Campinas, Caminas, Brazil

74. Michel Delforge, Leuven Cancer Institute at Leuven University College, Leuven, Belgium

75. Binod Dhakal, Medical College of Wisconsin, Milwaukee, WI

76. Madhav V. Dhodapkar, Winship Cancer Institute of Emory University, Atlanta, GA

77. Meletios A. Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece

78. David Dingli, Mayo Clinic, Rochester, MN

79. Angela Dispenzieri, Mayo Clinic, Rochester, MN

80. Kimberly Doucette, Medstar Georgetown University Hospital, Washington, DC

81. Johannes Drach, Confraternität Privatklinik Josefstadt, Wien, Austria

82. Matthew Drake, Hospital for Special Surgery, New York, NY

83. Christoph Driessen, Knatosspital St.Gallen, Gallen, Switzerland

84. Juan Du, Changzheng Hospital; Naval Medical University, Shanghai, China

85. Dominik Dytfeld, Poznań University of Medical Sciences, Pozán, Poland

86. Hermann Einsele, University Hospital Würzburg, Würzburg, Germany

87. Cristina Encinas, Hospital General Universitario Gregorio Marañón, Spain

88. Monika Engelhardt, Freiburg University Medical Center, Göttingen, Germany

89. Elías Eythorsson, University of Iceland, Reykjavík, Iceland

90. Thierry Facon, University of Lille, Lille, France

91. Dorotea Fantl, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

92. Jean-Paul Fermand, Hôpital Saint Louis, Paris, France

93. Carlos Fernández de Larrea, Hospital Clínic de Barcelona, Barcelona, Spain

94. Rafael Fonseca, Mayo Clinic, Scottsdale, AZ

95. Ciara Freeman, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

96. Reed Friend, Atrium Levine Cancer Center, Charlotte, NC

97. Gösta Gahrton, Karolinska Institute for Medicine, Huddinge, Sweden

98. Zhubin Gahvari, Medical College of Wisconsin, Madison, WI

99. Ramón García-Sanz, University Hospital of Salamanca, Salamanca, Spain

100. Laurent Garderet, Hôpital Pitié Salpêtrière, Paris, France

101. Alfred Garfall, University of Pennsylvania, Philadelphia, PA

102. Christina Gasparetto, Duke University Medical Center, Durham, NC

103. Maria Gavriatopoulou, Alexandra Hospital and Athens Medical School, Athens, Greece

104. Francesca Gay, University of Torino, Turin, Italy

105. Morie Gertz, Mayo Clinic, Rochester, MN

106. Irene Ghobrial, Dana-Farber Cancer Institute, Boston, MA

107. John Gibson, The University of Sydney, Camperdown, New South Wales, Australia

108. Peter Gimsing, Aarhus University Hospital, Aarhus, Denmark

109. Sergio A. Giralt, Memorial Sloan-Kettering Cancer Center, New York, NY

110. Siobhan Glavey, RCSI University of Medicine and Health Sciences, Dublin 9, Ireland

111. Hartmut Goldschmidt, University Hospital Heidelberg, Heidelberg, Germany

112. Wilson I. Gonsalves, Mayo Clinic, Rochester, MN

113. Verónica González de la Calle, University of Salamanca, Salamanca, Spain

114. Alessandro Gozzetti, University of Siena, Siena, Italy

115. Damian Green, Fred Hutchinson Cancer Research Center, Seattle, WA

116. Jingli Gu, The First Affiliated Hospital of Sun Yat-Sen University, Guangdong, China

117. Nina Gulbrandsen, Oslo Univesity Hospital, Oslo, Norway

118. Roman Hájek, University Hospital Ostrava, Ostrava, Czech Republic

119. Yervand Hakobyan, Armenian Hematology Association, Yerevan, Armenia

120. Doris Hansen, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

121. Izhar Hardan, Meir Medical Center, Kfar Saba, Israel

122. Jean-Luc Harousseau, University of Nantes, Nantes, France

123. Simon Harrison, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

124. Hamza Hashmi, Memorial Sloan-Kettering Cancer Center, New York, NY

125. Hamza Hassan, Roswell Park Comprehensive Cancer Center, Buffalo, NY

126. Hiroyuki Hata, Kumamoto University Hospital, Kumamoto, Japan

127. Yutaka Hattori, Keio University Faculty of Pharmacy, Tokyo, Japan

128. Patrick Hayden, St. James' Hospital, Dublin, Ireland

129. Leonard Heffner, Emory University, Atlanta, GA

130. Sylvie Hermouet, Centre Hospitalier Universitaire de Nantes, Nantes, France

131. Jens Hillengass, Roswell Park Comprehensive Cancer Center, Buffalo, NY

132. Joy Ho, Royal Prince Alfred Hospital, Sydney, Australia

133. Antje Hoering, Cancer Research and Biostatistics, Seattle, WA

134. James E. Hoffman, The University of Miami, Miami, FL

135. Sarah Holstein, University of Nebraska Medical Center, Omaha, NE

136. Dirk Hose, Vrije Universiteit Brussel, Brussels, Belgium

137. Jian Hou, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

138. Myo Htut, City of Hope National Medical Center, United States

139. Jeffrey (Shang-yi) Huang, National Taiwan University Hospital, Taipei, Taiwan

140. Malin Hultcrantz, Memorial Sloan Kettering Cancer Center, New York, NY

141. Vania Hungria, Clínica São Germano, São Paulo, Brazil

142. Shinsuke Iida, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

143. Sundar Jagannath, Icahn School of Medicine at Mount Sinai, New York, NY

144. Ishmael Jaiyesimi, William Beaumont Hospital, Royal Oak, MI

145. Andrzej J. Jakubowiak, University of Chicago, Chicago, IL

146. Murali Janakiram, City of Hope National Medical Center, Duarte, CA

147. Tomas Jelinek, University Hospital Ostrava, Ostrava, Czech Republic

148. Yogesh Jethava, Indiana Blood and Marrow Transplant Institute, Indianapolis, IN

149. Dragan Jevremovic, Mayo Clinic, Rochester, MN

150. Cristina João, Fundação Champalimaud and Champalimaud Center For The Unknown, Lisboa, Portugal

151. Nisha Joseph, Winship Cancer Institute of Emory University, Atlanta, GA

152. Douglas Joshua, The University of Sydney, New South Wales, Australia

153. Sung-Hoon Jung, Chonnam National University Hwasun Hospital, Jeollanam-do, South Korea

154. Artur Jurczyszyn, Jagiellonian University Department of Hematology, Kraków, Poland

155. Martin Kaiser, The Institute of Cancer Research, England, United Kingdom

156. Prashant Kapoor, Mayo Clinic, Rochester, MN

157. Efstathios Kastritis, National and Kapodistrian University of Athens School of Medicine, Athens, Greece

158. Eirini Katodritou, Theagenio Cancer Hospital, Thessaloniki, Greece

159. Jonathan Kaufman, Emory University School of Medicine, Atlanta, GA

160. Gurbakhash Kaur, University of Texas- Southwestern Medical Center, Dallas, TX

161. Michio Kawano, Kyoto University of Education, Ube, Japan

162. Leylagül Kaynar, Erciyes University, Kayseri, Turkey

163. Jonathon Keats, Translational Genomics Research Institute (TGen), Scottsdale, AZ

164. Jack Khouri, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

165. Kihyun Kim, Samsung Medical Center and Sungkyunkwan University School of Medicine, Suwon, South Korea

166. Neha Korde, Memorial Sloan Kettering Cancer Center, New York, NY

167. Taxiarchis Kourelis, Mayo Clinic, Rochester, MN

168. Eva Kovacs, Cancer Immunology Research-Life, Birsfelden, Switzerland

169. Maria Krauth, Medical University Vienna, Austria

170. Amrita Krishnan, City of Hope Medical Center, Newport Beach, CA

171. Sigurdur Y. Kristinsson, University of Iceland, Reykjavík, Iceland

172. Nicolaus Kröger, University Hospital Hamburg, Hamburg, Germany

173. Shaji Kumar, Mayo Clinic, MN

174. Robert Kyle, Mayo Clinic, MN

175. Chara Kyriakou, University College London Hospitals NHS Trust, England, United Kingdom

176. Martha Lacy, Mayo Clinic, Rochester, MN

177. Juan José Lahuerta, Hospital Universitario 12 de Octubre, Madrid, Spain

178. Ola Landgren, Sylvester Comprehensive Cancer Center University of Miami, Miami, FL

179. Alessandra Larocca, Divisione Universitaria di Ematologia, University of Torino, Torino, Italy

180. Jacob Laubach, Dana-Farber Cancer Institute, Boston, MA

181. Fernando Leal da Costa, Instituto Portugues De Oncologia, Lisboa, Portugal

182. Hans C. Lee, MD Anderson Cancer Center, Houston, TX

183. Jae-Hoon Lee, Gachon University Gil Medical Center, Incheon, South Korea

184. Je Jung Lee, Chonnam National University Hwasun Hospital, Gwangju, South Korea

185. Ji Hyun Lee, Dong-A University College of Medicine, Busan, South Korea

186. Merav Leiba, Chaim Sheba Medical Center, Tel Hashomer, Israel

187. Xavier Leleu, Hôpital La Mileterie at Centre Hospitalier Univeraitaire, Poitiers, France

188. Suzanne Lentzsch, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY

189. Nelson Leung, Mayo Clinic, Rochester, MN

190. Lisa Leypoldt, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

191. Edward N. Libby, Seattle Cancer Care Alliance, Seattle, WA

192. Eben Lichtman, The University of North Carolina at Chapel Hill, Chapel Hill, NC

193. Yi Lin, Mayo Clinic, Rochester, MN

194. Brea Lipe, University of Rochester Medical Center, Rochester, NY

195. Thorir Einarsson Long, University of ICELAND, Reykjavík, Iceland

196. Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, GA

197. Thorvardur Jon Love, University of ICELAND, Reykjavík, Iceland

198. Jin Lu, Peking University People's Hospital; Beijing University, Beijing, China

199. Heinz Ludwig, Wilhelminen Cancer Research Institute; Clinic Ottakring, Vienna, Austria

200. Deepu Madduri, Stanford University, Stanford, CA

201. Anuj Mahindra, Scripps Green Hospital, La Jolla, CA

202. Elias Mai, Heidelberg University Hospital, Heidelberg, Germany

203. Sham Mailankody, Memorial Sloan Kettering, New York, NY

204. Angelo Maiolino, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

205. Ehsan Malek, Case Western Reserve University, Cleveland, OH

206. Salomon Manier, University of Lille, Lille, France

207. Tomer Mark, University of Colorado—Anschutz Medical Campus, Aurora, CO

208. Thomas Martin, UCSF Helen Diller Family Comprehensive Cancer Center, CA

209. Deborah Martínez-Baños, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, Mexico

210. Joaquin Martinez-Lopez, Hospital 12 de Octubre, Madrid, Spain

211. Borja Puertas Martínez, University Hospital of Salamanca, Spain

212. Deborah Martínez-Baños, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico

213. María-Victoria Mateos, University Hospital of Salamanca, Salamanca, Spain

214. William Matsui, The University of Texas at Austin: Dell Medical School, Austin, TX

215. Francesco Maura, Memorial Sloan Kettering Cancer Center, New York, NY

216. Amitabha Mazumder, The Oncology Institute of Hope and Innovation, Pasadena, CA

217. Philip McCarthy, Roswell Park Comprehensive Cancer Center, Buffalo, NY

218. Georgia McCaughan, St Vincent's Hospital, Sydney, Australia

219. Arleigh McCurdy, The Ottawa Hospital, Ontario, Canada

220. Jayesh Mehta, Northwestern Memorial Hospital, Chicago, IL

221. Ulf-Henrik Mellqvist, Sahlgrenska University Hospital, Gothenburg, Sweden

222. Giampaolo Merlini, University of Pavia, Pavia, Italy

223. Christina Messiou, Institute of Cancer Research Biomedical Research Centre, Surrey, United Kingdom

224. Hira Mian, McMaster University, Hamilton, Ontario, Canada

225. Shonali Midha, Dana-Farber Cancer Institute, Boston, MA

226. Gábor Mikala, Centre Hospital of South-Pest, Budapest, Hungary

227. Joseph Mikhael, Translational Genomics Research Institute, Phoenix, AZ

228. Roberto Mina, AOU Città Della Salute E Della Scienza, University Of Torino, Torino, Italy

229. Monique Minnema, University Medical Center Utrecht, Utrecht, The Netherlands

230. Meera Mohan, Medical College of Wisconsin, Milwaukee, WI

231. Mohamad Mohty, Saint-Antoine Hospital, Paris, France

232. Jorge Monge, University of Colorado Anschutz Medical Campus, Aurora, CO

233. Kari Moore, Stavanger University Hospital, Stavanger, Norway

234. Philippe Moreau, University Hospital of Nantes, Nantes, France

235. Gareth Morgan, NYU Langone Health Perlmutter Cancer Center, New York, NY

236. Nikhil Munshi, Dana Farber Cancer Institute, Boston, MA

237. David Murray, Mayo Clinic, Rochester, MN

238. Juliane Garcez Musacchio, Casa de Saúde São José, Rio de Janeiro, Brazil

239. Omar Nadeem, Dana-Farber Cancer Institute, Boston, MA

240. Chandramouli Nagarajan, Singapore General Hospital, Singapore, Singapore

241. Hareth Nahi, Karolinska Institutet and Linköping University hospital, Stockholm, Sweden

242. Cristina Nanni, PET Centre in Bologna, Bologna, Italy

243. Weerasak Nawarawong, Chiang Mai University, Thailand

244. Paola Neri, University of Calgary: Arnie Charbonneau Cancer Institute, Alberta, Canada

245. Ruben Niesvizky, Weill Cornell Medicine, New York, NY

246. Ajay Nooka, Winship Cancer Institute of Emory University, Atlanta, GA

247. Hanne Norseth, Oslo University Hospital, Oslo, Norway

248. Amara Nouel, Hospital Ruiz y Paez, Universidad de oriente, Otro, Venezuela

249. Yana Novis, Hospital Sirio Libanes, São Paulo, Brazil

250. Ioannis Ntanasis-Stathopoulos, National and Kapodistrian University of Athens, Athens, Greece

251. Jakob Nørgaard, Oslo University Hospital, Oslo, Norway

252. Elizabeth O'Donnell, Massachusetts General Hospital, Boston, MA

253. Michael O'Dwyer, National University of IRELAND-Galway, Galway, Ireland

254. Peter O'Gorman, Mater Misericordiae University Hospital, Dublin, Ireland

255. Enrique Ocio, Marqués de Valdecilla University Hospital, Santander, Spain

256. Stefania Oliva, Università degli Studi di Torino, Piemonte, Italy

257. Alberto Orfao, University of Salamanca, Salamanca, Spain

258. Robert Orlowski, MD Anderson Cancer Center, Houston, TX

259. Jón Þórir Óskarsson, University of Iceland, Reykjavik, Iceland

260. Bruno Paiva, Clínica Universidad de Navarra: CIMA, Pamplona, Spain

261. Darren Pan, University of California San Francisco, San Francisco, CA

262. Samir Parekh, Icahn School of Medicine at Mount Sinai, New York, NY

263. Sung Soo Park, Seoul St. Mary’s Hospital, The Catholic University of Korea, Souel, South Korea

264. Harsh Parmar, Hackensack University Medical Center, Hackensack, NJ

265. Ricardo Parrondo, Mayo Clinic, Jacksonville, FL

266. Barry Paul, Levine Cancer Institute, Charlotte, NC

267. Krina Patel, MD Anderson Cancer Center, Houston, TX

268. Charlote Pawlyn, The Institute of Cancer Research, London, England, United Kingdom

269. Aurore Perrot, CHU de Toulouse, Toulouse Cedex, France

270. Pooja Phull, Hackensack University Medical Center, Hackensack, NJ

271. Linda Pilarski, University of Alberta, Alberta, Canada

272. Romanos Pistofidis, City of Hope, Duarte, CA

273. Rashesh Popat, University College London Hospitals NHS Foundation Trust, London, England, United Kingdom

274. Raymond Powles, Cancer Centre London, London, England, United Kingdom

275. Guy Pratt, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom

276. Noemí Puig, Hospital Universitario de Salamanca, Salamanca, Spain

277. Ben Puliafito, Massachusetts General Hospital, Boston, MA

278. Lugui Qiu, Institute of Hematology & Blood Diseases Hospital, Tianjin, China

279. Hang Quach, St.Vincent's Hospital, University of Melbourne, Melbourne, Australia

280. Marc Raab, Heidelberg University Hospital, Heidelberg, Germany

281. Noopur Raje, Massachusetts General Hospital, Boston, MA

282. S. Vincent Rajkumar, Mayo Clinic, Rochester, MN

283. Karthik Ramasamy, University of Oxford, Oxford, United Kingdom

284. Leo Rasche, University Hospital Würzburg, Würzburg, Germany

285. Donna Reece, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

286. Anthony Reiman, Saint John Regional Hospital, Stain John, New Brunswick, Canada

287. Guillermina Remaggi, Fundaleu, Buenos Aires, Argentina

288. Shambavi Richard, Icahn School of Medicine at Mount Sinai, New York, NY

289. Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA

290. Joshua Richter, Icahn School of Medicine at Mount Sinai: Tisch Cancer Institute, New York, NY

291. Eloísa Riva Serra, Hospital de Clinicas, Montevideo, Uruguay

292. Cesar Rodríguez, Icahn School of Medicine at Mount Sinai: Tisch Cancer Institute, New York, NY

293. Angelina Rodríguez Morales, Banco Municipal de Sangre de la Region Capital Caracas, Caracas, Venezuela

294. Paula Rodriguez Otero, Clinica Universidad de Navarra, Pamplona, Spain

295. David Roodman, Indiana University, Indianapolis, IN

296. Sæmundur Rögnvaldsson, University of Iceland, Reykjavík, Iceland

297. Catherine Rosales, St. Luke's Medical Center, Metro Manila, Philippines

298. Laura Rosiñol, Hospital Clínic Barcelona, Barcelona, Spain

299. Ashley Rosko, The Ohio State University, Columbus, OH

300. Adriana Rossi, Icahn School of Medicine at Mount Sinai, New York, NY

301. Murielle Roussel, University of Toulouse, Toulouse, France

302. Samuel M. Rubenstein, University of North Carolina-Chapel Hill, Chapel Hill, NC

303. Stephen Russell, Mayo Clinic, Rochester, MN

304. Mehmet Samur, Dana-Farber Cancer Institute, Boston, MA

305. Jesús San-Miguel, Clínica Universidad de Navarra, CCUN, Pamplona, Spain

306. Larysa Sanchez, Icahn School of Medicine at Mount Sinai: Tisch Cancer Institute, New York, NY

307. Douglas W. Sborov, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

308. Christoph Schaefers, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

309. Christof Scheid, University Hospital of Cologne, Germany

310. Fredrik Schjesvold, Oslo University Hospital, Oslo, Norway

311. Timothy Schmidt, University of Wisconsin School of Medicine and Public Health, Madison, WI

312. Rik Schots, Universitair Ziekenhuis Brussel, Brussel, Belgium

313. Natalia Schütz, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

314. Anja Seckinger, Vrije Universiteit Brussels, Brussel, Belgium

315. Sabina Sevcikova, Masaryk University, Brno, Czech Republic

316. Orhan Sezer, University Medical Center Hamburg—Eppendorf, Hamburg, Germany

317. Parth S. Shah, Dartmouth University Medical Center, Lebanon, NH

318. Mansi Shah, Rutgers Cancer Institute, New Brunswick, NJ

319. Kenneth Shain, H. Lee Moffitt Cancer Center, Tampa, FL

320. Kazuyuki Shimizu, Higashi Nagoya National Hospital, Nagoya, Japan

321. Karen Shires, University of Cape Town Medical School, Cape Town, South Africa

322. Chaim Shustik, McGill University Health Center, Montreal, Quebec, Canada

323. Surbhi Sidana, Stanford University, Stanford, CA

324. David Siegel, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ

325. Raija Silvennoinen, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

326. Seema Singhal, Northwestern Medicine, Chicago, IL

327. Tobias Slordahl, Norwegian University of Science and Technology, Trondheim, Norway

328. Pieter Sonneveld, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands

329. Andrew Spencer, The Alfred Hospital; Monash University, Melbourne, Australia

330. Adam Sperling, Dana-Farber Cancer Institute, Boston, MA

331. Edward Stadtmauer, University of Pennsylvania, Philadelphia, PA

332. Keith Stewart, University Health Network: Princess Margaret Cancer Centre, Toronto, Ontario, Canada

333. Agoston Szabo, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

334. Raphael E. Szalat, Boston University Medical Center, Boston, MA

335. Paola Tacchetti, Bologna University School of Medicine, Bologna, Italy

336. Hiroyuki Takamatsu, Institute of Transdisciplinary Sciences for Innovation, Kanazawa University, Japan

337. Alexis Talbot, Saint Louis Hospital, Paris, France

338. Carlyn Tan, Memorial Sloan Kettering Cancer Center, New York, NY

339. Daryl Tan, Clinic for Lymphoma, Myeloma and Blood Disorders, Singapore

340. Evangelos Terpos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece

341. Carolina Terragna, University of Bologna, Bologna, Italy

342. Santiago Thibaud, The Tisch Cancer Institute: Icahn School of Medicine at Mount Sinai, New York, NY

343. Sigrun Thorsteinsdóttir, University of Iceland, Reykjavik, Iceland

344. Patrizia Tosi, Italian Cooperative Group, Istituto di Ematologia Seragnoli, Bologna, Italy

345. Guido Tricot, University of Iowa Hospital and Clinics, Iowa City, IA

346. Suzanne Trudel, University Health Network: Princess Margaret Cancer Centre, Ontario, Canada

347. Sascha A. Tuchman, University of North Carolina—Chapel Hill, Chapel Hill, NC

348. Ingemar Turesson, Lund University Cancer Centre, Lund, Sweden

349. Saad Z. Usmani, Memorial Sloan Kettering Cancer Center, New York, NY

350. Ben Van Camp, Vrije Universiteit Brussels, Brussels, Belgium

351. Niels van de Donk, Vrije Universiteit Amsterdam Department of Hematology, Amsterdam, The Netherlands

352. Brian Van Ness, University of Minnesota, Minneapolis, MN

353. Ivan Van Riet, Vrine Universiteit Brussel, Brussels, Belgium

354. Isabelle Vande Broek, Vrije Universiteit Brussel, Brussels, Belgium

355. Karin Vanderkerken, Vrije Universiteit Brussel, Brussels, Belgium

356. Annette Vangsted, Copenhagen University Hospital, Copenhagen, Denmark

357. Cindy Varga, Levine Cancer Institute, Charlotte, NC

358. Robert Vescio, Cedars-Sinai Medical Center, Los Angeles, CA

359. David Vesole, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ

360. Ravi Vij, Washington University of Medicine, St Louis, MO

361. Alissa Visram, McMaster University, Canada

362. Dan Vogl, University of Pennsylvania, Philadelphia, PA

363. Peter Voorhees, Levine Cancer Institute, Charlotte, NC

364. Anders Waage, Norwegian University of Science and Technology, Trondheim, Norway

365. Brian Walker, University of Miami, Miami, FL

366. Michael Wang, The University of Texas M.D. Anderson Cancer Center, Houston, TX

367. Rahma Warsame, Mayo Clinic, Rochester, MN

368. Donna Weber, MD Anderson Cancer Center, Houston, TX

369. Neils Weinhold, University of Heidelberg, Heidelberg, Germany

370. Katja C. Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

371. Jan Westin, University of Gothenburg, Göteborg, Sweden

372. Baldeep Mona Wirk, Penn State Cancer Institute, Hershey, PA

373. Ralph Wäsch, University of Freiburg, Germany

374. Jing Christine Ye, MD Anderson Cancer Center, Houston, TX

375. Andrew Yee, Massachusetts General Hospital, Boston, MA

376. Kwee Yong, University College Hospital, London, England, United Kingdom

377. Dok Hyum Yoon, Asan Medical Center; University of Ulsan College of Medicine, Soeul, South Korea

378. Elena Zamagni, Seragnoli Institute of Hematology Università di Bologna, Bologna, Italy

379. Saurabh Zanwar, Mayo Clinic, Rochester, MN

380. Jeffrey Zonder, Karmanos Cancer Institute, Detroit, MI

381. Sonja Zweegman, VU University Medical Center, Amsterdam, The Netherlands

SUPPORT

Supported by the International Myeloma Foundation.

AUTHOR CONTRIBUTIONS

Conception and design: Efstathios Kastritis, Meletios A. Dimopoulos, Elena Zamagni

Collection and assembly of data: All authors

Data analysis and interpretation: All authors

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center .

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ( Open Payments ).

Efstathios Kastritis

Honoraria: Genesis Pharma, Janssen Oncology, Takeda, Prothena, Pfizer, GlaxoSmithKline

Consulting or Advisory Role: Janssen Oncology, Takeda, Genesis Pharma, Prothena, Pfizer

Research Funding: Janssen Oncology (Inst), Amgen (Inst), GlaxoSmithKline (Inst)

Travel, Accommodations, Expenses: Janssen Oncology, Genesis Pharma, Takeda, Pfizer

Shaji K. Kumar

Consulting or Advisory Role: Takeda (Inst), Janssen Oncology (Inst), Genentech/Roche (Inst), AbbVie (Inst), Bristol Myers Squibb/Celgene (Inst), Pfizer (Inst), Regeneron (Inst), Sanofi (Inst), K36 (Inst)

Research Funding: Takeda (Inst), AbbVie (Inst), Novartis (Inst), Sanofi (Inst), Janssen Oncology (Inst), MedImmune (Inst), Roche/Genentech (Inst), CARsgen Therapeutics (Inst), Allogene Therapeutics (Inst), GlaxoSmithKline (Inst), Regeneron (Inst), Bristol Myers Squibb/Celgene (Inst)

Travel, Accommodations, Expenses: AbbVie, Pfizer, Janssen, Beigene

Vincent S. Rajkumar

Honoraria: Research to Practice, Medscape

Patents, Royalties, Other Intellectual Property: Authorship Royalties from Up To Date

Wee Joo Chng

Honoraria: Johnson and Johnson, Amgen, Celgene, Takeda, AbbVie

Research Funding: Janssen (Inst), Celgene (Inst), Amgen (Inst)

Luciano Costa

Honoraria: Amgen, Janssen, Karyopharm Therapeutics, Sanofi, Adaptive Biotechnologies, AbbVie, Bristol Myers Squibb/Celgene/Juno, Caribou Biosciences, Pfizer

Consulting or Advisory Role: Amgen, Adaptive Biotechnologies, Bristol Myers Squibb/Celgene, Janssen, AbbVie, Sanofi, Pfizer

Research Funding: Janssen (Inst), Amgen (Inst), Bristol Myers Squibb/Celgene/Juno (Inst), Caribou Biosciences (Inst), AbbVie (Inst)

Monika Engelhardt

Honoraria: J+J

Travel, Accommodations, Expenses: J+J

Wilson Gonsalves

Consulting or Advisory Role: Amgen (Inst)

Research Funding: ORIC Pharmaceuticals (Inst), Bristol Myers Squibb Foundation (Inst)

Patents, Royalties, Other Intellectual Property: Patent number: 10996224: Assessing and treating precursor plasma cell disorders

Vania Hungria

Consulting or Advisory Role: AbbVie, Takeda, Sanofi, BMS Brazil, Amgen, Pfizer, GlaxoSmithKline, Regeneron, Roche, Johnson & Johnson

Speakers' Bureau: Janssen-Cilag, Takeda, BMS Brazil, Sanofi, Amgen, GlaxoSmithKline, AbbVie, Pfizer

Jens Hillengass

Employment: Roswell Park Cancer Institute

Honoraria: Janssen Biotech, BeiGene, Targeted Oncology, IntegrityCE, Cancer Network, The Binding Site, Decera Clinical Insights, Curio Science, Clinical Care Options, Plexus

Consulting or Advisory Role: Janssen Biotech, Regeneron, Sebia, Prothena, Angitia, Regeneron, Pfizer, Siemens Healthineers, Bristol Myers Squibb/Celgene

Research Funding: Celgene (Inst), GlaxoSmithKline (Inst), Bristol Myers Squibb/Celgene (Inst)

Patents, Royalties, Other Intellectual Property: “Discovering anti-CXCR2 inhibitor alone or in combination with standard of care for the treatment of multiple myeloma”—RP23-023/809466-01 US provisional patent application 63/546,942

Dragan Jevremovic

Consulting or Advisory Role: UpToDate

Eirini Katodritou

Honoraria: Takeda, Janseen-Cilag, Amgen, Pfizer, GlaxoSmithKline

Consulting or Advisory Role: Johnson & Johnson/Janssen, GlaxoSmithKline, Amgen, Swixx BioPharma

Research Funding: Takeda, Amgen, Janseen-Cilag, Genesis Pharma, AbbVie, Karyopharm Therapeutics, Pfizer, Bristol Myers Squibb/Celgene

Travel, Accommodations, Expenses: Takeda, Johnson & Johnson/Janssen

Sagar Lonial

Stock and Other Ownership Interests: TG Therapeutics

Consulting or Advisory Role: Celgene, Bristol Myers Squibb, Janssen Oncology, Novartis, GlaxoSmithKline, Amgen, AbbVie, Takeda, Merck, Sanofi, Pfizer, Regeneron

Research Funding: Celgene, Bristol Myers Squibb, Takeda, Janssen Oncology, Novartis

Other Relationship: TG Therapeutics

Heinz Ludwig

Consulting or Advisory Role: Amgen, Janssen-Cilag, Sanofi

Speakers' Bureau: Celgene, Bristol Myers Squibb, Janssen-Cilag, Amgen, Takeda, Pfizer

Research Funding: Amgen (Inst), Sanofi (Inst)

Philip McCarthy

Stock and Other Ownership Interests: Lilly, Novo Nordisk, Beam Therapeutics, Vertex, AbbVie (I), Abbott Laboratories (I), Johnson & Johnson/Janssen

Honoraria: Bristol Myers Squibb, Oncopeptides, Karyopharm Therapeutics

Consulting or Advisory Role: Bristol Myers Squibb, Karyopharm Therapeutics, Legend Biotech

Research Funding: Celgene (Inst)

Patents, Royalties, Other Intellectual Property: Provisional Patent Award: RP23-023/809466-01 US provisional application 63/546, 962—Discovering Anti-CXCR2 Inhibitor alone or in Combination with Standard of Care for Treatment of Multiple Myeloma—003551.01150

Elias Mai

Honoraria: Janssen, Takeda, Bristol Myers Squibb/Celgene, Sanofi, GlaxoSmithKline, Stemline Therapeutics, Oncopeptides

Consulting or Advisory Role: Janssen, Bristol Myers Squibb/Celgene, Takeda, Sanofi, GlaxoSmithKline, Stemline Therapeutics, Oncopeptides

Research Funding: Janssen, Bristol Myers Squibb/Celgene, Takeda, Sanofi, GlaxoSmithKline

Travel, Accommodations, Expenses: Janssen, Bristol Myers Squibb/Celgene, Takeda, GlaxoSmithKline, Sanofi, Stemline Therapeutics

Salomon Manier

Consulting or Advisory Role: Amgen (Inst), Janssen Oncology (Inst), Pfizer (Inst), Adaptive Biotechnologies (Inst), Celgene/Bristol Myers Squibb (Inst), Sanofi (Inst), Regeneron (Inst), Roche/Genentech (Inst), Predicta (Inst)

Tom Martin

Consulting or Advisory Role: GlaxoSmithKline, Pfizer, Lilly, AstraZeneca, AbbVie

Research Funding: Sanofi (Inst), AMGEN (Inst), Janssen Oncology (Inst), BMSi

Maria-Victoria Mateos

This author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.

Honoraria: Janssen-Cilag, Celgene, Amgen, GlaxoSmithKline, AbbVie/Genentech, Sanofi, Pfizer

Consulting or Advisory Role: Takeda, Janssen-Cilag, Celgene, Amgen, AbbVie, GlaxoSmithKline, Pfizer, Regeneron, Roche/Genentech, Stemline Therapeutics, Kite, a Gilead company

Hira Mian

Honoraria: Janssen, Takeda, Pfizer, Amgen, Sanofi, Bristol Myers Squibb/Medarex, AbbVie, Regeneron, Roche

Research Funding: Pfizer (Inst)

Joseph Mikhael

Honoraria: Sanofi, Janssen, Bristol Myers Squibb USA, Menarini

Research Funding: Bristol Myers Squibb/Celgene (Inst)

Philippe Moreau

This author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.

Honoraria: Celgene, Janssen-Cilag, Amgen, GlaxoSmithKline, AbbVie, Sanofi, Pfizer

Consulting or Advisory Role: Celgene, Janssen, Amgen, GlaxoSmithKline, Sanofi, AbbVie, Pfizer

Nikhil C. Munshi

Stock and Other Ownership Interests: OncoPep, C4 Therapeutics, Raqia, Koi Therapeutics

Consulting or Advisory Role: Janssen, OncoPep, AbbVie, Adaptive Biotechnologies, Bristol Myers Squibb, Bristol Myers Squibb/Celgene, Legend Biotech, Novartis, Sebia, Pfizer, GlaxoSmithKline, Genentech, Regeneron

Patents, Royalties, Other Intellectual Property: Oncopep

Bruno Paiva

Honoraria: Sanofi, Roche/Genentech, Adaptive Biotechnologies, GlaxoSmithKline, Bristol Myers Squibb/Celgene, Johnson & Johnson/Janssen, Becton Dickinson, The Binding Site

Consulting or Advisory Role: Sanofi, Bristol Myers Squibb/Celgene, Johnson & Johnson/Janssen, Roche/Genentech

Research Funding: Sanofi (Inst), Roche/Genentech (Inst), GlaxoSmithKline (Inst), BeiGene (Inst), Bristol Myers Squibb/Celgene

Travel, Accommodations, Expenses: Bristol Myers Squibb/Celgene

Charlotte Pawlyn

Honoraria: Janssen Oncology (Inst), Sanofi (Inst), Celgene/Bristol Myers Squibb (Inst), GlaxoSmithKline (Inst), Adaptive Biotechnologies (Inst), Amgen (Inst), AstraZeneca (Inst), CellCentric (Inst), Kite/Gilead (Inst), ITeos Therapeutics (Inst), Pfizer (Inst), Menarini (Inst), Opna Bio (Inst)

Research Funding: Janssen (Inst)

Leo Rasche

Honoraria: Johnson & Johnson/Janssen, GlaxoSmithKline, Pfizer, Roche, Sanofi, BMS GmbH & Co. KG

Consulting or Advisory Role: Johnson & Johnson/Janssen, Pfizer, BMS GmbH & Co. KG

Research Funding: BMS GmbH & Co. KG

Joshua Richter

Consulting or Advisory Role: Takeda, Adaptive Biotechnologies, Karyopharm Therapeutics, Antengene, Sanofi, Genentech, Pfizer, Janssen, AbbVie, Bristol Myers Squibb/Celgene, Regeneron

Speakers' Bureau: Celgene, Janssen, Bristol Myers Squibb, Sanofi, Adaptive Biotechnologies

Travel, Accommodations, Expenses: Regeneron

Jesús San Miguel

Consulting or Advisory Role: Amgen (Inst), Celgene (Inst), Takeda (Inst), Bristol Myers Squibb (Inst), MSD (Inst), Novartis (Inst), Sanofi (Inst), Janssen (Inst), Roche (Inst), AbbVie (Inst), GlaxoSmithKline (Inst), Karyopharm Therapeutics (Inst), Secura Bio (Inst), Regeneron (Inst), Haemalogix (Inst), Pfizer (Inst), Kite, a Gilead company (Inst), Dr. Reddy's (Inst)

Douglas W. Sborov

Consulting or Advisory Role: Sanofi, GlaxoSmithKline, Bristol Myers Squibb/Celgene, Janssen, Pfizer, Arcellx, AstraZeneca, Opna Bio, Caribou Biosciences, Regeneron

Research Funding: Pfizer, Regeneron, Johnson & Johnson/Janssen

Saad Z. Usmani

Consulting or Advisory Role: Janssen Oncology, GlaxoSmithKline, AbbVie, Bristol Myers Squibb/Celgene, Regeneron, AstraZeneca, Sanofi

Research Funding: Janssen Oncology, Bristol Myers Squibb, K36 Therapeutics, AbbVie, Regeneron

Meletios A. Dimopoulos

This author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.

Honoraria: Amgen, Takeda, Janssen-Cilag, Bristol Myers Squibb, Beigene, Sanofi, Regeneron, Menarini, AstraZeneca, Swixx BioPharma, GlaxoSmithKline

Consulting or Advisory Role: Amgen, Janssen-Cilag, Takeda, Bristol Myers Squibb, Beigene, Sanofi, Regeneron, Menarini, Swixx BioPharma, GlaxoSmithKline, AstraZeneca

Travel, Accommodations, Expenses: Amgen, Janssen, Takeda, Bristol Myers Squibb/Celgene

Elena Zamagni

Honoraria: Janssen-Cilag, Celgene, Amgen, Bristol Myers Squibb, Takeda, GlaxoSmithKline, Oncopeptides, Sanofi, Pfizer, Roche, AstraZeneca

Consulting or Advisory Role: Celgene, Janssen-Cilag, Amgen, Sanofi, Pfizer, BMS GmbH & Co. KG, AstraZeneca, GlaxoSmithKline, Menarini, Menarini

Travel, Accommodations, Expenses: Janssen-Cilag, Celgene, Amgen, Sanofi, Oncopeptides, Pfizer, GlaxoSmithKline

No other potential conflicts of interest were reported.

Efstathios Kastritis

Honoraria: Genesis Pharma, Janssen Oncology, Takeda, Prothena, Pfizer, GlaxoSmithKline

Consulting or Advisory Role: Janssen Oncology, Takeda, Genesis Pharma, Prothena, Pfizer

Research Funding: Janssen Oncology (Inst), Amgen (Inst), GlaxoSmithKline (Inst)

Travel, Accommodations, Expenses: Janssen Oncology, Genesis Pharma, Takeda, Pfizer

Shaji K. Kumar

Consulting or Advisory Role: Takeda (Inst), Janssen Oncology (Inst), Genentech/Roche (Inst), AbbVie (Inst), Bristol Myers Squibb/Celgene (Inst), Pfizer (Inst), Regeneron (Inst), Sanofi (Inst), K36 (Inst)

Research Funding: Takeda (Inst), AbbVie (Inst), Novartis (Inst), Sanofi (Inst), Janssen Oncology (Inst), MedImmune (Inst), Roche/Genentech (Inst), CARsgen Therapeutics (Inst), Allogene Therapeutics (Inst), GlaxoSmithKline (Inst), Regeneron (Inst), Bristol Myers Squibb/Celgene (Inst)

Travel, Accommodations, Expenses: AbbVie, Pfizer, Janssen, Beigene

Vincent S. Rajkumar

Honoraria: Research to Practice, Medscape

Patents, Royalties, Other Intellectual Property: Authorship Royalties from Up To Date

Wee Joo Chng

Honoraria: Johnson and Johnson, Amgen, Celgene, Takeda, AbbVie

Research Funding: Janssen (Inst), Celgene (Inst), Amgen (Inst)

Luciano Costa

Honoraria: Amgen, Janssen, Karyopharm Therapeutics, Sanofi, Adaptive Biotechnologies, AbbVie, Bristol Myers Squibb/Celgene/Juno, Caribou Biosciences, Pfizer

Consulting or Advisory Role: Amgen, Adaptive Biotechnologies, Bristol Myers Squibb/Celgene, Janssen, AbbVie, Sanofi, Pfizer

Research Funding: Janssen (Inst), Amgen (Inst), Bristol Myers Squibb/Celgene/Juno (Inst), Caribou Biosciences (Inst), AbbVie (Inst)

Monika Engelhardt

Honoraria: J+J

Travel, Accommodations, Expenses: J+J

Wilson Gonsalves

Consulting or Advisory Role: Amgen (Inst)

Research Funding: ORIC Pharmaceuticals (Inst), Bristol Myers Squibb Foundation (Inst)

Patents, Royalties, Other Intellectual Property: Patent number: 10996224: Assessing and treating precursor plasma cell disorders

Vania Hungria

Consulting or Advisory Role: AbbVie, Takeda, Sanofi, BMS Brazil, Amgen, Pfizer, GlaxoSmithKline, Regeneron, Roche, Johnson & Johnson

Speakers' Bureau: Janssen-Cilag, Takeda, BMS Brazil, Sanofi, Amgen, GlaxoSmithKline, AbbVie, Pfizer

Jens Hillengass

Employment: Roswell Park Cancer Institute

Honoraria: Janssen Biotech, BeiGene, Targeted Oncology, IntegrityCE, Cancer Network, The Binding Site, Decera Clinical Insights, Curio Science, Clinical Care Options, Plexus

Consulting or Advisory Role: Janssen Biotech, Regeneron, Sebia, Prothena, Angitia, Regeneron, Pfizer, Siemens Healthineers, Bristol Myers Squibb/Celgene

Research Funding: Celgene (Inst), GlaxoSmithKline (Inst), Bristol Myers Squibb/Celgene (Inst)

Patents, Royalties, Other Intellectual Property: “Discovering anti-CXCR2 inhibitor alone or in combination with standard of care for the treatment of multiple myeloma”—RP23-023/809466-01 US provisional patent application 63/546,942

Dragan Jevremovic

Consulting or Advisory Role: UpToDate

Eirini Katodritou

Honoraria: Takeda, Janseen-Cilag, Amgen, Pfizer, GlaxoSmithKline

Consulting or Advisory Role: Johnson & Johnson/Janssen, GlaxoSmithKline, Amgen, Swixx BioPharma

Research Funding: Takeda, Amgen, Janseen-Cilag, Genesis Pharma, AbbVie, Karyopharm Therapeutics, Pfizer, Bristol Myers Squibb/Celgene

Travel, Accommodations, Expenses: Takeda, Johnson & Johnson/Janssen

Sagar Lonial

Stock and Other Ownership Interests: TG Therapeutics

Consulting or Advisory Role: Celgene, Bristol Myers Squibb, Janssen Oncology, Novartis, GlaxoSmithKline, Amgen, AbbVie, Takeda, Merck, Sanofi, Pfizer, Regeneron

Research Funding: Celgene, Bristol Myers Squibb, Takeda, Janssen Oncology, Novartis

Other Relationship: TG Therapeutics

Heinz Ludwig

Consulting or Advisory Role: Amgen, Janssen-Cilag, Sanofi

Speakers' Bureau: Celgene, Bristol Myers Squibb, Janssen-Cilag, Amgen, Takeda, Pfizer

Research Funding: Amgen (Inst), Sanofi (Inst)

Philip McCarthy

Stock and Other Ownership Interests: Lilly, Novo Nordisk, Beam Therapeutics, Vertex, AbbVie (I), Abbott Laboratories (I), Johnson & Johnson/Janssen

Honoraria: Bristol Myers Squibb, Oncopeptides, Karyopharm Therapeutics

Consulting or Advisory Role: Bristol Myers Squibb, Karyopharm Therapeutics, Legend Biotech

Research Funding: Celgene (Inst)

Patents, Royalties, Other Intellectual Property: Provisional Patent Award: RP23-023/809466-01 US provisional application 63/546, 962—Discovering Anti-CXCR2 Inhibitor alone or in Combination with Standard of Care for Treatment of Multiple Myeloma—003551.01150

Elias Mai

Honoraria: Janssen, Takeda, Bristol Myers Squibb/Celgene, Sanofi, GlaxoSmithKline, Stemline Therapeutics, Oncopeptides

Consulting or Advisory Role: Janssen, Bristol Myers Squibb/Celgene, Takeda, Sanofi, GlaxoSmithKline, Stemline Therapeutics, Oncopeptides

Research Funding: Janssen, Bristol Myers Squibb/Celgene, Takeda, Sanofi, GlaxoSmithKline

Travel, Accommodations, Expenses: Janssen, Bristol Myers Squibb/Celgene, Takeda, GlaxoSmithKline, Sanofi, Stemline Therapeutics

Salomon Manier

Consulting or Advisory Role: Amgen (Inst), Janssen Oncology (Inst), Pfizer (Inst), Adaptive Biotechnologies (Inst), Celgene/Bristol Myers Squibb (Inst), Sanofi (Inst), Regeneron (Inst), Roche/Genentech (Inst), Predicta (Inst)

Tom Martin

Consulting or Advisory Role: GlaxoSmithKline, Pfizer, Lilly, AstraZeneca, AbbVie

Research Funding: Sanofi (Inst), AMGEN (Inst), Janssen Oncology (Inst), BMSi

Maria-Victoria Mateos

This author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.

Honoraria: Janssen-Cilag, Celgene, Amgen, GlaxoSmithKline, AbbVie/Genentech, Sanofi, Pfizer

Consulting or Advisory Role: Takeda, Janssen-Cilag, Celgene, Amgen, AbbVie, GlaxoSmithKline, Pfizer, Regeneron, Roche/Genentech, Stemline Therapeutics, Kite, a Gilead company

Hira Mian

Honoraria: Janssen, Takeda, Pfizer, Amgen, Sanofi, Bristol Myers Squibb/Medarex, AbbVie, Regeneron, Roche

Research Funding: Pfizer (Inst)

Joseph Mikhael

Honoraria: Sanofi, Janssen, Bristol Myers Squibb USA, Menarini

Research Funding: Bristol Myers Squibb/Celgene (Inst)

Philippe Moreau

This author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.

Honoraria: Celgene, Janssen-Cilag, Amgen, GlaxoSmithKline, AbbVie, Sanofi, Pfizer

Consulting or Advisory Role: Celgene, Janssen, Amgen, GlaxoSmithKline, Sanofi, AbbVie, Pfizer

Nikhil C. Munshi

Stock and Other Ownership Interests: OncoPep, C4 Therapeutics, Raqia, Koi Therapeutics

Consulting or Advisory Role: Janssen, OncoPep, AbbVie, Adaptive Biotechnologies, Bristol Myers Squibb, Bristol Myers Squibb/Celgene, Legend Biotech, Novartis, Sebia, Pfizer, GlaxoSmithKline, Genentech, Regeneron

Patents, Royalties, Other Intellectual Property: Oncopep

Bruno Paiva

Honoraria: Sanofi, Roche/Genentech, Adaptive Biotechnologies, GlaxoSmithKline, Bristol Myers Squibb/Celgene, Johnson & Johnson/Janssen, Becton Dickinson, The Binding Site

Consulting or Advisory Role: Sanofi, Bristol Myers Squibb/Celgene, Johnson & Johnson/Janssen, Roche/Genentech

Research Funding: Sanofi (Inst), Roche/Genentech (Inst), GlaxoSmithKline (Inst), BeiGene (Inst), Bristol Myers Squibb/Celgene

Travel, Accommodations, Expenses: Bristol Myers Squibb/Celgene

Charlotte Pawlyn

Honoraria: Janssen Oncology (Inst), Sanofi (Inst), Celgene/Bristol Myers Squibb (Inst), GlaxoSmithKline (Inst), Adaptive Biotechnologies (Inst), Amgen (Inst), AstraZeneca (Inst), CellCentric (Inst), Kite/Gilead (Inst), ITeos Therapeutics (Inst), Pfizer (Inst), Menarini (Inst), Opna Bio (Inst)

Research Funding: Janssen (Inst)

Leo Rasche

Honoraria: Johnson & Johnson/Janssen, GlaxoSmithKline, Pfizer, Roche, Sanofi, BMS GmbH & Co. KG

Consulting or Advisory Role: Johnson & Johnson/Janssen, Pfizer, BMS GmbH & Co. KG

Research Funding: BMS GmbH & Co. KG

Joshua Richter

Consulting or Advisory Role: Takeda, Adaptive Biotechnologies, Karyopharm Therapeutics, Antengene, Sanofi, Genentech, Pfizer, Janssen, AbbVie, Bristol Myers Squibb/Celgene, Regeneron

Speakers' Bureau: Celgene, Janssen, Bristol Myers Squibb, Sanofi, Adaptive Biotechnologies

Travel, Accommodations, Expenses: Regeneron

Jesús San Miguel

Consulting or Advisory Role: Amgen (Inst), Celgene (Inst), Takeda (Inst), Bristol Myers Squibb (Inst), MSD (Inst), Novartis (Inst), Sanofi (Inst), Janssen (Inst), Roche (Inst), AbbVie (Inst), GlaxoSmithKline (Inst), Karyopharm Therapeutics (Inst), Secura Bio (Inst), Regeneron (Inst), Haemalogix (Inst), Pfizer (Inst), Kite, a Gilead company (Inst), Dr. Reddy's (Inst)

Douglas W. Sborov

Consulting or Advisory Role: Sanofi, GlaxoSmithKline, Bristol Myers Squibb/Celgene, Janssen, Pfizer, Arcellx, AstraZeneca, Opna Bio, Caribou Biosciences, Regeneron

Research Funding: Pfizer, Regeneron, Johnson & Johnson/Janssen

Saad Z. Usmani

Consulting or Advisory Role: Janssen Oncology, GlaxoSmithKline, AbbVie, Bristol Myers Squibb/Celgene, Regeneron, AstraZeneca, Sanofi

Research Funding: Janssen Oncology, Bristol Myers Squibb, K36 Therapeutics, AbbVie, Regeneron

Meletios A. Dimopoulos

This author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.

Honoraria: Amgen, Takeda, Janssen-Cilag, Bristol Myers Squibb, Beigene, Sanofi, Regeneron, Menarini, AstraZeneca, Swixx BioPharma, GlaxoSmithKline

Consulting or Advisory Role: Amgen, Janssen-Cilag, Takeda, Bristol Myers Squibb, Beigene, Sanofi, Regeneron, Menarini, Swixx BioPharma, GlaxoSmithKline, AstraZeneca

Travel, Accommodations, Expenses: Amgen, Janssen, Takeda, Bristol Myers Squibb/Celgene

Elena Zamagni

Honoraria: Janssen-Cilag, Celgene, Amgen, Bristol Myers Squibb, Takeda, GlaxoSmithKline, Oncopeptides, Sanofi, Pfizer, Roche, AstraZeneca

Consulting or Advisory Role: Celgene, Janssen-Cilag, Amgen, Sanofi, Pfizer, BMS GmbH & Co. KG, AstraZeneca, GlaxoSmithKline, Menarini, Menarini

Travel, Accommodations, Expenses: Janssen-Cilag, Celgene, Amgen, Sanofi, Oncopeptides, Pfizer, GlaxoSmithKline

No other potential conflicts of interest were reported.

REFERENCES

1. Swerdlow SH, Campo E, Pileri SA, et al. : The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375-2390, 2016

2. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538-e548, 2014

3. Alaggio R, Amador C, Anagnostopoulos I, et al. : The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms. Leukemia 36:1720-1748, 2022

4. Katodritou E, Terpos E, Symeonidis AS, et al. : Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek Myeloma Study Group in 97 patients. Am J Hematol 89:803-808, 2014

5. Finsinger P, Grammatico S, Chisini M, et al. : Clinical features and prognostic factors in solitary plasmacytoma. Br J Haematol 172:554-560, 2016

6. Chang WI, Koh HK, Yoon SS, et al. : The predictive value of serum myeloma protein in solitary plasmacytoma. Radiat Oncol J 38:129-137, 2020

7. Ganzel C, Trestman S, Levi S, et al. : Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: A report of the Israeli Myeloma Study Group. Leuk Lymphoma 63:3448-3455, 2022

8. Nakaya A, Tanaka H, Yagi H, et al. : Retrospective analysis of plasmacytoma in Kansai Myeloma Forum Registry. Int J Hematol 112:666-673, 2020

9. Sasaki R, Yasuda K, Abe E, et al. : Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy. Int J Radiat Oncol Biol Phys 82:626-634, 2012

10. Thumallapally N, Meshref A, Mousa M, et al. : Solitary plasmacytoma: Population-based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer 17:13, 2017

11. Manasanch EE, Kunacheewa C, Claussen CM, et al. : Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. Blood Cancer J 11:17, 2021

12. Mignot F, Schernberg A, Arsene-Henry A, et al. : Solitary plasmacytoma treated by lenalidomide-dexamethasone in combination with radiation therapy: Clinical outcomes. Int J Radiat Oncol Biol Phys 106:589-596, 2020

13. Sharpley FA, Neffa P, Panitsas F, et al. : Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era. PLoS ONE 14:e0219857, 2019

14. Knobel D, Zouhair A, Tsang RW, et al. : Prognostic factors in solitary plasmacytoma of the bone: A multicenter Rare Cancer Network study. BMC Cancer 6:118, 2006

15. Ozsahin M, Tsang RW, Poortmans P, et al. : Outcomes and patterns of failure in solitary plasmacytoma: A multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys 64:210-217, 2006

16. Albano D, Bosio G, Treglia G, et al. : 18F-FDG PET/CT in solitary plasmacytoma: Metabolic behavior and progression to multiple myeloma. Eur J Nucl Med Mol Imaging 45:77-84, 2018

17. Alghisi A, Borghetti P, Maddalo M, et al. : Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience. J Cancer Res Clin Oncol 147:1773-1779, 2021

18. Katodritou E: Characteristics and survival outcomes of solitary plasmacytomas: A 30-year experience of the Greek Myeloma Study Group on 175 patients. Am J Hematol, 100:1334-1342, 2025

19. Charalampous C, Claveau JS, Kapoor P, et al. : Solitary plasmacytoma: Single-institution experience, and systematic review and meta-analysis of clinical outcomes. Blood Adv 9:1559-1570, 2025

20. Dores GM, Landgren O, McGlynn KA, et al. : Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: Incidence and survival in the United States, 1992-2004. Br J Haematol 144:86-94, 2009

21. Mousavi SE, Ilaghi M, Aslani A, et al. : A population-based study on incidence trends of myeloma in the United States over 2000-2020. Sci Rep 13:20705, 2023

22. Ellington TD, Henley SJ, Wilson RJ, et al. : Trends in solitary plasmacytoma, extramedullary plasmacytoma, and plasma cell myeloma incidence and myeloma mortality by racial-ethnic group, United States 2003-2016. Cancer Med 10:386-395, 2021

23. Wang Y, Li H, Liu C, et al. : Solitary plasmacytoma of bone of the spine: Results from Surveillance, Epidemiology, and End Results (SEER) registry. Spine 44:E117-E125, 2019

24. Nahi H, Genell A, Walinder G, et al. : Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. Eur J Haematol 99:216-222, 2017

25. Dimopoulos MA, Moulopoulos LA, Maniatis A, et al. : Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 96:2037-2044, 2000

26. Galieni P, Cavo M, Pulsoni A, et al. : Clinical outcome of extramedullary plasmacytoma. Haematologica 85:47-51, 2000

27. Knowling MA, Harwood AR, Bergsagel DE: Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol 1:255-262, 1983

28. Thumallapally N, Meshref A, Mousa M, et al. : Erratum to: Solitary plasmacytoma: Population-based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer 17:443, 2017

29. Ghodke K, Shet T, Epari S, et al. : A retrospective study of correlation of morphologic patterns, MIB1 proliferation index, and survival analysis in 134 cases of plasmacytoma. Ann Diagn Pathol 19:117-123, 2015

30. Reed V, Shah J, Medeiros LJ, et al. : Solitary plasmacytomas: Outcome and prognostic factors after definitive radiation therapy. Cancer 117:4468-4474, 2011

31. Dispenzieri A: POEMS syndrome: Update on diagnosis, risk-stratification, and management. Am J Hematol 98:1934-1950, 2023

32. Lipsker D, Rondeau M, Massard G, et al. : The AESOP (adenopathy and extensive skin patch overlying a plasmacytoma) syndrome: Report of 4 cases of a new syndrome revealing POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) syndrome at a curable stage. Medicine 82:51-59, 2003

33. de Waal EG, Leene M, Veeger N, et al. : Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands. Br J Haematol 175:661-667, 2016

34. Susnerwala SS, Shanks JH, Banerjee SS, et al. : Extramedullary plasmacytoma of the head and neck region: Clinicopathological correlation in 25 cases. Br J Cancer 75:921-927, 1997

35. Remigio PA, Klaum A: Extramedullary plasmacytoma of stomach. Cancer 27:562-568, 1971

36. Chim CS, Wong WM, Nicholls J, et al. : Extramedullary sites of involvement in hematologic malignancies: Case 3. Hemorrhagic gastric plasmacytoma as the primary presentation in multiple myeloma. J Clin Oncol 20:344-347, 2002

37. Kumar S, Fonseca R, Dispenzieri A, et al. : Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood 101:1715-1717, 2003

38. Bink K, Haralambieva E, Kremer M, et al. : Primary extramedullary plasmacytoma: Similarities with and differences from multiple myeloma revealed by interphase cytogenetics. Haematologica 93:623-626, 2008

39. Boll M, Parkins E, O'Connor SJ, et al. : Extramedullary plasmacytoma are characterized by a ‘myeloma-like’ immunophenotype and genotype and occult bone marrow involvement. Br J Haematol 151:525-527, 2010

40. Yadav U, Kumar SK, Baughn LB, et al. : Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas. Blood 142:1871-1878, 2023

41. Burroni B, Harel S, Seror R, et al. : Molecular profiling and risk stratification in solitary bone plasmacytoma. Leukemia 39:2568-2572, 2025

42. Elsayad K, Oertel M, Konig L, et al. : Maximizing the clinical benefit of radiotherapy in solitary plasmacytoma: An international multicenter analysis. Cancers 12:676, 2020

43. Hill QA, Rawstron AC, de Tute RM, et al. : Outcome prediction in plasmacytoma of bone: A risk model utilizing bone marrow flow cytometry and light-chain analysis. Blood 124:1296-1299, 2014

44. Paiva B, Chandia M, Vidriales MB, et al. : Multiparameter flow cytometry for staging of solitary bone plasmacytoma: New criteria for risk of progression to myeloma. Blood 124:1300-1303, 2014

45. Fend F, Dogan A, Cook JR: Plasma cell neoplasms and related entities-evolution in diagnosis and classification. Virchows Arch 482:163-177, 2023

46. Bartl R, Frisch B, Fateh-Moghadam A, et al. : Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol 87:342-355, 1987

47. Shao H, Xi L, Raffeld M, et al. : Nodal and extranodal plasmacytomas expressing immunoglobulin A: An indolent lymphoproliferative disorder with a low risk of clinical progression. Am J Surg Pathol 34:1425-1435, 2010

48. Yadav R, Sun L, Cheema A, et al. : Amyloidoma and plasmacytoma presented as a solitary lung nodule in a patient of multiple myeloma with AL-Amyloidosis: A case report and review of literature. J Invest Med High Impact Case Rep 11:23247096231184768, 2023

49. Werner BC, Shen FH, Shimer AL: Primary cervical amyloidoma: A case report and review of the literature. Spine J 13:e1-e7, 2013

50. Pinheiro JP, Carneiro D, Tavares S, et al. : Management and outcome of solitary spinal amyloidoma—A systematic literature review. World Neurosurg 140:325-331, 2020

51. Kirkel DM, Paal E, Ascensao J, et al. : Multiple bony amyloidomas as an initial presentation of myeloma. Clin Lymphoma Myeloma 9:E18-E20, 2009

52. Jones JB, Lopez-Hisijos N, Berkman RA, et al. : AL amyloidosis manifesting as a vertebral amyloidoma secondary to an unrecognized plasmacytoma expressing cyclin D1 case report. Int J Surg Case Rep 121:110000, 2024

53. Giorgi PD, Pallotta ML, Legrenzi S, et al. : Spinal cord compression in dialysis-related upper cervical amyloidoma—A case report. Spinal Cord Ser Cases 7:40, 2021

54. Carter JM, Howe BM, Inwards CY: Conditions simulating primary bone neoplasms. Surg Pathol Clin 10:731-748, 2017

55. Agrawal M, Batra VV, Majumdar K, et al. : Extensive osteolytic skull base amyloidoma simulating malignancy: A rare pseudotumor producing a diagnostic dilemma. J Cancer Res Ther 11:646, 2015

56. Abbas N, George K, Dardis R: Primary amyloidoma of the thoracic spine causing paraparesis. Br J Neurosurg 22:286-288, 2008

57. Zhou T, Cheng J, Karrs J, et al. : Clinicopathologic and molecular characterization of Epstein-Barr Virus-positive plasmacytoma. Am J Surg Pathol 46:1364-1379, 2022

58. Riddle ND, Bui MM: Fibrous dysplasia. Arch Pathol Lab Med 137:134-138, 2013

59. Chang CY, Garner HW, Ahlawat S, et al. : Society of Skeletal Radiology—White Paper. Guidelines for the diagnostic management of incidental solitary bone lesions on CT and MRI in adults: Bone reporting and data system (Bone-RADS). Skeletal Radiol 51:1743-1764, 2022

60. Moulopoulos LA, Koutoulidis V, Hillengass J, et al. : Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: A report of the IMWG Bone Working Group. Blood Cancer J 8:95, 2018

61. Farooq U, Choudhary S, McLeod MP, et al. : Adenopathy and extensive skin patch overlying a plasmacytoma (AESOP) syndrome. J Clin Aesthet Dermatol 5:25-27, 2012

62. Rongioletti F, Failla MC, Atzori L, et al. : Skin manifestations of POEMS and AESOP syndrome in the same patient revealing plasma cell dyscrasia. J Cutan Pathol 43:1167-1171, 2016

63. Lenormand C, Marzolf G, Lipsker D: AESOP syndrome: A potential life-saving and early clue to the diagnosis of POEMS syndrome. Clin Dermatol 39:215-219, 2021

64. Yan W, Lv R, Xu J, et al. : Adenopathy and extensive skin patch overlying a plasmacytoma (AESOP) syndrome: A case report and literature review. Ann Hematol 103:339-341, 2024

65. Melloni G, Carretta A, Ciriaco P, et al. : Inflammatory pseudotumor of the lung in adults. Ann Thorac Surg 79:426-432, 2005

66. Deshpande V, Zen Y, Chan JK, et al. : Consensus statement on the pathology of IgG4-related disease. Mod Pathol 25:1181-1192, 2012

67. Hillengass J, Usmani S, Rajkumar SV, et al. : International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 20:e302-e312, 2019

68. Hillengass J, Moulopoulos LA, Delorme S, et al. : Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: A study of the International Myeloma Working Group. Blood Cancer J 7:e599, 2017

69. Cavo M, Terpos E, Nanni C, et al. : Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: A consensus statement by the International Myeloma Working Group. Lancet Oncol 18:e206-e217, 2017

70. Dimopoulos MA, Hillengass J, Usmani S, et al. : Role of magnetic resonance imaging in the management of patients with multiple myeloma: A consensus statement. J Clin Oncol 33:657-664, 2015

71. Caers J, Withofs N, Hillengass J, et al. : The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. Haematologica 99:629-637, 2014

72. Gleeson TG, Moriarty J, Shortt CP, et al. : Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skeletal Radiol 38:225-236, 2009

73. Kropil P, Fenk R, Fritz LB, et al. : Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma. Eur Radiol 18:51-58, 2008

74. Moulopoulos LA, Dimopoulos MA, Weber D, et al. : Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol 11:1311-1315, 1993

75. Wilder RB, Ha CS, Cox JD, et al. : Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer 94:1532-1537, 2002

76. Liebross RH, Ha CS, Cox JD, et al. : Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol 52:245-249, 1999

77. Dimopoulos MA, Terpos E, Boccadoro M, et al. : EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol 22:680-700, 2025

78. Messiou C, Hillengass J, Delorme S, et al. : Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology 291:5-13, 2019

79. Fouquet G, Guidez S, Herbaux C, et al. : Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma. Clin Cancer Res 20:3254-3260, 2014

80. Lu YY, Chen JH, Lin WY, et al. : FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple myeloma: A systematic review and meta-analysis. Clin Nucl Med 37:833-837, 2012

81. Salaun PY, Gastinne T, Frampas E, et al. : FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. Haematologica 93:1269-1271, 2008

82. Kim PJ, Hicks RJ, Wirth A, et al. : Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys 74:740-746, 2009

83. Zamagni E, Nanni C, Patriarca F, et al. : A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 92:50-55, 2007

84. Gómez León N, Vicuña-Andrés I, Aguado-Bueno B, et al. : Whole-body MRI versus [18F]FDG PET/CT in diagnosing and monitoring plasmacytomas: A comparative study. Clin Nucl Med 50:695-706, 2025

85. Nanni C, Versari A, Chauvie S, et al. : Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): Final results. IMPeTUs (Italian Myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging 45:712-719, 2018

86. Corwin J, Lindberg RD: Solitary plasmacytoma of bone vs. extramedullary plasmacytoma and their relationship to multiple myeloma. Cancer 43:1007-1013, 1979

87. McLain RF, Weinstein JN: Solitary plasmacytomas of the spine: A review of 84 cases. J Spinal Disord 2:69-74, 1989

88. Frassica DA, Frassica FJ, Schray MF, et al. : Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys 16:43-48, 1989

89. Warsame R, Gertz MA, Lacy MQ, et al. : Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol 87:647-651, 2012

90. Bataille R, Sany J: Solitary myeloma: Clinical and prognostic features of a review of 114 cases. Cancer 48:845-851, 1981

91. Bender S, Javaugue V, Saintamand A, et al. : Immunoglobulin variable domain high-throughput sequencing reveals specific novel mutational patterns in POEMS syndrome. Blood 135:1750-1758, 2020

92. Gao S, Wang YT, Ma GY, et al. : Solitary bone plasmacytoma: Long-term clinical outcomes in a single center. Curr Probl Cancer 50:101095, 2024

93. Sanoja-Flores L, Flores-Montero J, Garcés JJ, et al. : Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J 8:117, 2018

94. Liebross RH, Ha CS, Cox JD, et al. : Solitary bone plasmacytoma: Outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys 41:1063-1067, 1998

95. Holland J, Trenkner DA, Wasserman TH, et al. : Plasmacytoma. Treatment results and conversion to myeloma. Cancer 69:1513-1517, 1992

96. Ascione S, Harel S, Besson FL, et al. : Chemotherapy in solitary bone plasmacytoma to prevent evolution to multiple myeloma. Haematologica 108:3160-3164, 2023

97. Dingli D, Kyle RA, Rajkumar SV, et al. : Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 108:1979-1983, 2006

98. Dasari S, Kohlhagen MC, Dispenzieri A, et al. : Detection of plasma cell disorders by mass spectrometry: A comprehensive review of 19,523 cases. Mayo Clinic Proc 97:294-307, 2022

99. Tsang RW, Gospodarowicz MK, Pintilie M, et al. : Solitary plasmacytoma treated with radiotherapy: Impact of tumor size on outcome. Int J Radiat Oncol Biol Phys 50:113-120, 2001

100. Mauro GP, Neffa PP, Villar RC, et al. : Impact of bone events on survival in solitary bone plasmacytoma. Rep Pract Oncol Radiother 25:389-395, 2020

101. Oertel M, Elsayad K, Kroeger KJ, et al. : Impact of radiation dose on local control and survival in extramedullary head and neck plasmacytoma. Radiat Oncol 14:63, 2019

102. Ouyang H, Han S, Jiang L, et al. : Reossification and prognosis following radiotherapy with/without surgery for spinal solitary plasmacytoma of the bone: A retrospective study of 39 patients. Spine J 20:283-291, 2020

103. Barzenje DA, Kolstad A, Ghanima W, et al. : Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years. Hematological Oncol 36:217-223, 2018

104. Tournier-Rangeard L, Lapeyre M, Graff-Caillaud P, et al. : Radiotherapy for solitary extramedullary plasmacytoma in the head-and-neck region: A dose greater than 45 Gy to the target volume improves the local control. Int J Radiat Oncol Biol Phys 64:1013-1017, 2006

105. Agbuduwe C, Yang H, Gaglani J, et al. : Clinical presentation and outcomes of solitary plasmacytoma in a tertiary hospital in the UK. Clin Med 20:e191-e195, 2020

106. Soutar R, Lucraft H, Jackson G, et al. : Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol 124:717-726, 2004

107. Barosi G, Boccadoro M, Cavo M, et al. : Management of multiple myeloma and related-disorders: Guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica 89:717-741, 2004

108. Terpos E, Morgan G, Dimopoulos MA, et al. : International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 31:2347-2357, 2013

109. Goyal G, Bartley AC, Funni S, et al. : Treatment approaches and outcomes in plasmacytomas: Analysis using a national dataset. Leukemia 32:1414-1420, 2018

110. Tsang RW, Campbell BA, Goda JS, et al. : Radiation therapy for solitary plasmacytoma and multiple myeloma: Guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 101:794-808, 2018

111. Khan MK, Nasti TH, Qian JY, et al. : Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: A prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA. Lancet Haematol 11:e510-e520, 2024

112. Mark D, Gilbo P, Meshrekey R, et al. : Local radiation therapy for palliation in patients with multiple myeloma of the spine. Front Oncol 9:601, 2019

113. Lee JW, Lee JE: Local radiotherapy for palliation in multiple myeloma patients with symptomatic bone lesions. Radiat Oncol J 34:59-63, 2016

114. Rades D, Hoskin PJ, Stalpers LJ, et al. : Short-course radiotherapy is not optimal for spinal cord compression due to myeloma. Int J Radiat Oncol Biol Phys 64:1452-1457, 2006

115. Dimopoulos MA, Pouli A, Anagnostopoulos A, et al. : Macrofocal multiple myeloma in young patients: A distinct entity with favorable prognosis. Leuk Lymphoma 47:1553-1556, 2006

116. Jawad MU, Scully SP: Skeletal Plasmacytoma: Progression of disease and impact of local treatment; an analysis of SEER database. J Hematol Oncol 2:41, 2009

117. Wen G, Wang W, Zhang Y, et al. : Management of extramedullary plasmacytoma: Role of radiotherapy and prognostic factor analysis in 55 patients. Chin J Cancer Res 29:438-446, 2017

118. Yeoh KW, Thitsar SM, Master Z, et al. : Pleural plasmacytomas—The role of radiotherapy. Br J Haematol 190:e160-e162, 2020

119. Bachar G, Goldstein D, Brown D, et al. : Solitary extramedullary plasmacytoma of the head and neck—Long-term outcome analysis of 68 cases. Head Neck 30:1012-1019, 2008

120. Zhu X, Wang L, Zhu Y, et al. : Extramedullary plasmacytoma: Long-term clinical outcomes in a single-center in China and literature review. Ear Nose Throat J 100:227-232, 2021

121. Venkatesulu B, Mallick S, Giridhar P, et al. : Pattern of care and impact of prognostic factors on the outcome of head and neck extramedullary plasmacytoma: A systematic review and individual patient data analysis of 315 cases. Eur Arch Otorhinolaryngol 275:595-606, 2018

122. Zhang C, Su Z, Zhang J, et al. : Prognostic factors and outcomes of extramedullary plasmacytoma in 451 patients in China. Leuk Res 53:11-17, 2017

123. Gerry D, Lentsch EJ: Epidemiologic evidence of superior outcomes for extramedullary plasmacytoma of the head and neck. Otolaryngol Head Neck Surg 148:974-981, 2013

124. Kyriakou C, Molloy S, Vrionis F, et al. : The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: A consensus statement from the International Myeloma Working Group (IMWG). Blood Cancer J 9:27, 2019

125. Malhotra K, Butler JS, Yu HM, et al. : Spinal disease in myeloma: Cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing. BMC Cancer 16:444, 2016

126. Molloy S, Sewell MD, Platinum J, et al. : Is balloon kyphoplasty safe and effective for cancer-related vertebral compression fractures with posterior vertebral body wall defects? J Surg Oncol 113:835-842, 2016

127. Thalambedu N, Kamran M, Al-Hadidi S: The role of vertebral augmentation procedures in the management of multiple myeloma. Clin Hematol Int 6:51-58, 2024

128. Huang W, Cao D, Ma J, et al. : Solitary plasmacytoma of cervical spine: Treatment and prognosis in patients with neurological lesions and spinal instability. Spine 35:E278-E284, 2010

129. Alexiou C, Kau RJ, Dietzfelbinger H, et al. : Extramedullary plasmacytoma: Tumor occurrence and therapeutic concepts. Cancer 85:2305-2314, 1999

130. Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, et al. : A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J 2012:1-6, 2012

131. Oliveira RC, Amaro P, Juliao MJ, et al. : Primary gastric plasmacytoma: A rare entity. BMJ Case Rep 2017:bcr2016218967, 2017;2017d

132. Brummund D, Sinyor B: A rare case of extramedullary plasmacytoma presenting as large abdominal mass. Cureus 12:e9740, 2020

133. Iosif E, Rees C, Beeslaar S, et al. : Gastrointestinal bleeding as initial presentation of extramedullary plasma cell neoplasms: A case report and review of the literature. World J Gastrointest Endosc 11:308-321, 2019

134. Aviles A, Huerta-Guzman J, Delgado S, et al. : Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol 14:111-117, 1996

135. Mayr NA, Wen BC, Hussey DH, et al. : The role of radiation therapy in the treatment of solitary plasmacytomas. Radiother Oncol 17:293-303, 1990

136. Mheidly K, Lamy De La Chapelle T, Hunault M, et al. : New insights in the treatment of patients with solitary bone plasmacytoma. Leuk Lymphoma 60:2810-2813, 2019

137. Suh YG, Suh CO, Kim JS, et al. : Radiotherapy for solitary plasmacytoma of bone and soft tissue: Outcomes and prognostic factors. Ann Hematol 91:1785-1793, 2012

138. Bolek TW, Marcus RB, Mendenhall NP: Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys 36:329-333, 1996

139. Shih LY, Dunn P, Leung WM, et al. : Localised plasmacytomas in Taiwan: Comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone. Br J Cancer 71:128-133, 1995

140. Delauche-Cavallier MC, Laredo JD, Wybier M, et al. : Solitary plasmacytoma of the spine. Long-term clinical course. Cancer 61:1707-1714, 1988

141. Zamagni E, Nanni C, Dozza L, et al. : Standardization of 18 F-FDG-PET/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J Clin Oncol 39:116-125, 2021

142. Weberpals J, Pulte D, Jansen L, et al. : Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21. Haematologica 102:e229-e232, 2017

143. Harwood AR, Knowling MA, Bergsagel DE: Radiotherapy of extramedullary plasmacytoma of the head and neck. Clin Radiol 32:31-36, 1981

144. Galieni P, Cavo M, Pulsoni A, et al. : Clinical outcome of extramedullary plasmacytoma. Haematologica 85:257-264, 2000

145. Alongi P, Zanoni L, Incerti E, et al. : 18F-FDG PET/CT for early postradiotherapy assessment in solitary bone plasmacytomas. Clin Nucl Med 40:e399-e404, 2015

146. Gomez Leon N, Aguado Bueno B, Herreros Perez M, et al. : Agreement between 18F-FDG PET/CT and whole-body magnetic resonance compared with skeletal survey for initial staging and response at end-of-treatment evaluation of patients with multiple myeloma. Clin Nucl Med 46:310-322, 2021

147. Messiou C, Porta N, Sharma B, et al. : Prospective evaluation of whole-body MRI versus FDG PET/CT for lesion detection in participants with myeloma. Radiol Imaging Cancer 3:e210048, 2021

148. Nanni C, Zamagni E, Farsad M, et al. : Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: Preliminary results. Eur J Nucl Med Mol Imaging 33:525-531, 2006

149. Spinnato P, Bazzocchi A, Brioli A, et al. : Contrast enhanced MRI and (1)(8)F-FDG PET-CT in the assessment of multiple myeloma: A comparison of results in different phases of the disease. Eur J Radiol 81:4013-4018, 2012

150. Schmit GD, Kurup AN, Morris JM, et al. : Percutaneous cryoablation of plasmacytomas: Oncologic effectiveness and adverse events. J Vasc Interv Radiol 34:1303-1310, 2023